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 Summary 
1 Summary 
1.1 German Summary 
Prionenerkrankungen sind neurodegenerative Erkrankungen, neuropathologisch 
charakterisiert durch spongiforme Vakuolenbildungen im Hirngewebe, den Verlust 
neuronaler Zellen sowie die verstärkte Proliferation von Mikroglia und Astroglia. 
Die molekularen Mechanismen für eine derartige Prionen-vermittelte 
Neurodegeneration sind jedoch nicht vollständig aufgeklärt. In jüngster 
Vergangenheit wurden Beobachtungen gemacht, die annehmen lassen, dass eine 
zytosolische fehlgefaltete Form des zellulären Prionproteins (PrP
C) der Auslöser 
für solch einen neuronalen Zelltod sein könnte. Dabei wird angenommen, dass 
eine Beeinträchtigung des proteasomalen Proteolysesystems eine Ursache für 
diese zytosolische Akkumulation von PrP darstellt. Die Akkumulation von 
zytosolischem PrP ist entweder die Folge eines Rücktransports von unreifem 
nicht-nativ gefaltetem PrP aus dem endoplasmatischen Retikulum (ER), welches 
unter diesen Bedingungen nicht abgebaut wird (ER-assoziierter Abbau, ERAD) 
oder ist zurückzuführen auf einen unzureichenden post-translationalen ER-Import 
bei gesteigerter Genexpression. In der Tat wurde in vivo und in vitro ein 
zytotoxisches Potential für ein zytosolisch exprimiertes PrP (Cy-PrP) gezeigt. Mit 
Hilfe kultivierter Zelllinien wurden diesbezüglich jedoch widersprüchliche 
Ergebnisse publiziert, die nicht für eine generelle Toxizität des Cy-PrPs sprechen. 
Dennoch könnte eine Cy-PrP-vermittelte neuronale Toxizität eine zentrale Rolle 
bei der Pathogenese von Prionenerkrankungen spielen. Um diesem Mechanismus 
detaillierter auf den Grund zu gehen, wurden in dieser Studie neuronale N2a 
Zellen etabliert, die Cy-PrP sowohl transient induzierbar als auch stabil 
exprimieren.  
Mit Hilfe dieses Zellmodells konnten folgende Beobachtungen gemacht werden: 
Erstens, die transiente Expression von Cy-PrP über einen Zeitraum von 24 h und 
48 h war nicht ausreichend, um im signifikanten Maßstab Zelltod in neuronalen 
Zellen zu induzieren. Dazu wurde zum einen die Vitalität der Zellen mittels MTT-
Test gemessen. Zum anderen wurde die Freisetzung von Lactat-Dehydrogenase 
(LDH) aus den Zellen bestimmt zur Abschätzung der Cy-PrP vermittelten 
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Zytotoxizität. Um diese Daten zu untermauern wurde zusätzlich getestet, ob eine 
Cy-PrP Expression zu einer spezifischen Aktivierung der Caspase-3 führt, einem 
zentralen Parameter innerhalb der Apoptose-Signalwege. Auch hier konnte keine 
Cy-PrP spezifische Caspase-3-Aktivierung nachgewiesen werden. Um zelltyp-
abhängige Effekte auszuschließen wurde das Cy-PrP in nicht-neuronalen Zellen 
exprimiert, zeigte jedoch auch hier keinen zytotoxischen Effekt in den MTT-
Vitalitätstests.  
Auf Grund der postulierten biochemischen Ähnlichkeiten von Cy-PrP und PrP
Sc 
wurde das Cy-PrP im zweiten Teil der Arbeit bezüglich seiner Proteinase K-
Resistenz, seiner Halbwertszeit und intrazellulären Proteolyse näher 
charakterisiert. Ersteres wurde ermittelt durch den Verdau der Zelllysate mit 
unterschiedlichen Protease K-Konzentrationen gefolgt von Immunoblotanalysen 
zur Detektion der resistenten Cy-PrP-Mengen. Im Gegensatz zum PrP
Sc, welches 
kontinuierlich von den als positive Kontrolle eingesetzten N2a58/22L-Zellen 
gebildet wird, wurde das Cy-PrP durch die Proteinase-K-Behandlung vollständig 
verdaut. Zur Bestimmung der Halbwertszeiten von Cy-PrP und dem vollständigen 
Prionprotein (PM-PrP) wurden Degradationsexperimente durchgeführt. Mit Hilfe 
der dazu durchgeführten Immunoblotanalysen konnte ein intrazellulärer Abbau 
des Cy-PrPs beobachtet werden. Dabei war die Abbaukinetik des Cy-PrPs 
vergleichbar mit der des PM-PrPs. Nähere Untersuchungen mit Hilfe des 
proteasomalen Inhibitors Epoxomicin zeigten, dass die Cy-PrP-Proteolyse 
Proteasom-vermittelt ist. Im Vergleich dazu erfolgte der Abbau des reifen, 
glycosylierten PM-PrPs unabhängig von der Inhibitorzugabe und war demzufolge 
nicht Proteasom-vermittelt.  
Drittens, obwohl die Cy-PrP-Proteolyse durch das Proteasom erfolgt, hatte die 
Überexpression von Cy-PrP keinen Einfluß auf die intrazelluläre 
Proteasomaktivität und das proteasomale Expressionslevel. Um zu untersuchen, 
ob eine Beeinträchtigung der Proteasomaktivität eine Cy-PrP-vermittelte 
Zytotoxizität auslösen kann, wurden MTT-Tests in Anwesenheit des spezifischen 
Proteasominhibitors Epoxomicin durchgeführt. Trotz Inhibition des Proteasoms 
konnte nach 24 stündiger Cy-PrP-Expression keine Cy-PrP-vermittelte 
Zytotoxizität detektiert werden.  
Viertens, intrazelluläre Lokalisationsstudien mit Hilfe von Fraktionierungs-
experimenten und Immunofluoreszenzanalysen ergaben eine inhomogene 
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intrazelluläre Verteilung des Cy-PrPs, charakterisiert durch starke Aggregat-
ähnliche Detektionsmuster in den Immunofluoreszenzanalysen. Dieses 
Lokalisationsmuster wurde sowohl in den transient exprimierenden Zellen als auch 
in den stabilen N2a-Cy-PrP Zelllinien beobachtet. Kolokalisationsstudien mit 
verschiedenen Zellkompartment-spezifischen Markern ergaben keine ER- und 
Golgi-Lokalisation für das Cy-PrP. Dagegen wurde das PM-PrP wie erwartet 
Membran-ständig und im Golgi detektiert. Interessanterweise konnte hier gezeigt 
werden, dass die großen intrazellulären Cy-PrP-Akkumulationsherde mit 
endosomalen EEA-1 positiven Vesikeln und mit Hsc70, der konstitutiven Form des 
Hsp70, kolokalisierten. Dabei war zu beobachten, dass das zytosolische Hsc70 in 
den Mock-Kontrollen und PM-PrP-exprimierenden Zellen intrazellulär homogen 
verteilt war. Die Expression von Cy-PrP verursachte jedoch eine zelluläre 
Umverteilung  von Hsc70, beobachtbar als Aggregat-ähnliches Detektionsmuster 
in den Immunofluoreszenzanalysen. Dabei hatte die Expression von Cy-PrP oder 
PM-PrP keinen Einfluß auf das Expressionslevel von Hsc70, analysiert in 
Immunoblotexperimenten.  
Fünftens, in dieser Arbeit gelang es zum ersten Mal stabile Cy-PrP-exprimierende 
Zelllinien zu etablieren. Dabei wurden zwei verschiedene Parentalzelllinien 
verwendet – die neuronalen N2a Zellen und die PrP
0/0 neuronalen Vorläufer-
Zellen. Diese Zelllinien zeigten keine Anzeichen von Apoptose wie verringerte 
Proliferation oder Chromatinkondensation. In den PrP
0/0 neuronalen Vorläufer-
Zellen kolokalisierte das Cy-PrP ebenfalls mit endosomalen EEA-1 positiven 
Vesikeln und mit Hsc70.  
Diese Ergebnisse lassen den Schluß zu, dass allein das Auftreten von 
zytosolischem PrP nicht primär den neuronalen Zelltod initiieren muß. Zusätzlich 
könnte die effiziente Entfernung des Cy-PrPs aus dem Zytosol durch einen 
gezielten Transport in endosomale Vesikel eine erfolgreiche Methode sein, um 
eine toxische zytosolische PrP-Akkumulation zu unterbinden, was letztendlich von 
Zelltyp zu Zelltyp in seiner Leistungsfähigkeit variieren kann. Die beobachtete 
Kolokalisation von Cy-PrP und Hsc70 in solchen endosomalen Vesikeln könnte 
ein erster Hinweis darauf sein, dass Hsc70 eine wichtige Regulatorfunktion bei der 
kontrollierten Entstehung von amorphen Cy-PrP Aggregaten und deren Transport 
in endosomale Vesikel übernimmt. Diese Hsc70-abhängige Translokation von Cy-
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PrP könnte einen wesentlichen Schutzmechanismus gegen eine toxische 
Akkumulation von Cy-PrP in N2a-Zellen widerspiegeln.  
1.2 English Summary 
Prion diseases are a complex group of fatal neurodegenerative disorders with a 
broad host spectrum, which are characterised by strong neuronal cell loss, 
spongiform vacuolation and astrocytic proliferation. The molecular mechanisms of 
prion-mediated neurodegeneration are not yet fully understood. Recently, it has 
been proposed that neuronal cell death might be triggered by cytosolic 
accumulation of misfolded cellular prion protein (PrP
C) due to impairment of 
proteasomal degradation. Cytosolic PrP
C could result from either retro-
translocation via the endoplasmatic reticulum-associated degradation system 
(ERAD) or abortive translocation of PrP
C into the ER. Indeed, expression of 
cytosolic PrP (Cy-PrP) was shown to be neurotoxic both in vivo and in vitro. 
However, contradicting results on cytosolic PrP-mediated neurotoxicity in cultured 
cells have been reported. Cytosolic PrP–mediated cytotoxicity may play a central 
role in the pathogenesis of prion diseases. In order to investigate the molecular 
mechanisms of this process, a detailed analysis of N2a cells conditionally 
expressing cytosolic PrP (Cy-PrP) was performed in this study. The following 
results were obtained: First, Cy-PrP expression is not per se sufficient to trigger 
cytotoxicity in N2a cells independently of proteasome inhibition. Second, Cy-PrP is 
degraded with kinetics resembling the degradation of cell membrane-anchored 
full-length PM-PrP. In this process, the 20/26S proteasome was responsible for 
Cy-PrP degradation while the proteolysis of matured full length PM-PrP is not 
affected by the proteasomal system. Third, Cy-PrP accumulates in fine foci when 
expressed at high levels and co-localises with the cytosolic chaperone Hsc70 in 
EEA-1 positive endocytic vesicles. From these data it was proposed that the 
chaperone Hsc70 acts as a regulator for the controlled formation of amorphous 
Cy-PrP aggregates and their transport to endosomal vesicles. This Hsc70-
dependent mechanism may confer protection to N2a cells against toxic 
accumulation of Cy-PrP in the cytosol. 
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2 Introduction 
2.1 Prion diseases and infectivity 
In the past decade, transmissible spongiform encephalopathies (TSE) or prion 
diseases have achieved enhanced attention in the media due to the appearance of 
bovine spongiform encephalopathy (BSE) or “mad cow disease” in the UK. Due to 
the potential for human infection, BSE has strongly influenced medical, 
agricultural, economic and political issues in Europe and (Chesebro, 2003). 
Presently, Scrapie (Sc), BSE and CWD are the most prominent prion diseases in 
the animal kingdom (Chesebro, 2003). Creutzfeldt-Jacob disease (CJD), kuru, 
Gerstmann-Sträussler-Scheinker disease (GSS), fatal familial insomnia (FFI) and 
new variant of Creutzfeldt-Jacob disease (vCJD) are the prion diseases in human. 
Irrespective of their sporadic, infectious or familial origin, the prion diseases are 
transmissible disorders in which infectivity is associated with the replication and 
accumulation of PrP-scrapie (PrP
Sc), a disease-related insoluble form of the host 
derived cellular prion protein (PrP
C). According to the “protein-only” hypothesis, 
PrP
Sc is the infectious agent that may convert PrP
C to PrP
Sc in a self-propagating 
reaction (Prusiner, 1998). Additionally, different experimental data have 
demonstrated that transmission of infectivity is closely connected to PrP
C 
(Brandner et al., 1996b; Bueler et al., 1993; Legname et al., 2004; Prusiner et al., 
1993). Recently, it has been shown that PrP
C has to be membrane anchored to 
mediate transmission of PrP
Sc-infectivity (Chesebro et al., 2005). 
The clinical symptoms of TSE diseases vary in humans. They have in common a 
progressive development of severe motoric disturbance and dementia leading to 
death within few months to several years after diagnosis, which can be years to 
decades after the initial infection in transmissible cases.  
Neuropathology of prion disease is characterised by extensive neuronal death, 
accompanied by spongiform vacuolation as well as astro- and microgliosis, usually 
combined with widespread deposits of extracellular amyloid aggregates. These 
aggregates often contain the causative agent PrP
Sc. Abnormal PrP accumulation 
occurs in the majority of, but not all, prion diseases. 
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2.2 Cellular prion protein  
2.2.1 Characteristics and structure of PrP
C 
Murine PrP
C is a glycoprotein encoded by the highly conserved prion protein gene, 
Prnp, containing three exons with the open reading frame (ORF) in exon 3 (Fig. 5). 
Transcription of the ORF sequence and its translation generates PrP with a size of 
253 amino acids (Fig. 1). The N-terminal signal peptide (NSP) of the precursor 
form of the prion protein directs PrP through the endoplasmatic reticulum (ER) and 
the Golgi apparatus to the cell surface. PrP
C is N-glycosylated at two asparagin 
residues located in the C-terminal part of PrP (aa 181 and 197) (Bolton et al., 
1985). Attachment of a glycosylphosphatidylinositol (GPI) anchor occurs at 
position 231 of PrP (Stahl et al., 1987).  
 
 
 
Fig. 1  Structure of the prion protein. (A) The cellular prion protein consists of a flexible N-
terminal and a globular C-terminal domain. The C-terminal structure contains mainly α-helical 
arrangements and two small β-sheet secondary elements. The N-terminus possesses the copper-
binding octarepeats; the protein has a signal peptide (NSP) for membrane targeting and is post-
translationally modified by addition of two glycosylations as well as a glycosylphosphatidylinositol 
(GPI) membrane anchor. (B) The nuclear magnetic resonance (NMR) derived structure of mouse 
PrP (121-231) contains a two stranded anti-parallel beta-sheet and three alpha-helices (Riek et al., 
1996a). 
In addition, a single disulfide bridge is formed between the cysteine residues at 
position 179 and 214 (Safar et al., 1990). PrP
C is attached to the cell membrane 
through the GPI anchor (Stahl et al., 1987). 
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The three-dimensional structure of PrP
C, determined by nuclear magnetic 
resonance (NMR) spectroscopy (Fig. 1B) and circular dichroism analysis of 
recombinant murine PrP (Hornemann et al., 1997; Riek et al., 1996b; Riek et al., 
1997), consists of a disordered N-terminal region (aa 1-120) and a C-terminal 
region (121-231) composed of three α-helices and two β-strands flanking the first 
α-helix (Fig. 1A). Although the primary structure of PrP
C and PrP
Sc are the same, 
the two isoforms are very different at the level of secondary structure. PrP
Sc has a 
much higher proportion of β-sheets than PrP
C (45% compared to 3%) (Prusiner, 
1998). Typically, PrP
C occurs as non-, mono- and diglycosylated form correlating 
with a molecular weight of 27-35 kDa in immunoblot analyses and is, in contrast to 
the pathological PrP
Sc, sensitive to proteinase K (PK) treatment. Although the Prnp 
gene is highly conserved as well as the three-dimensional protein structure of 
PrPs from different species are quite similar, there exist some differences in the 
primary structure of PrPs in different species. The latter allows distinguishing PrPs 
from different species by specific anti-PrP antibodies. In this study a chimerical 
mouse-hamster-mouse PrP, called MH2M PrP (Scott et al., 1993) was 
overexpressed in neuronal cells. The transgene MH2M PrP contains an epitope, 
which is not present in murine PrP. This epitope is specifically recognised by the 
3F4 antibody and allows distinguishing between host-derived murine PrP and 
transgene PrP. 
2.2.2 Biosynthesis and endosomal trafficking of PrP
C 
The biosynthetic pathway followed by PrP
C is similar to that of other membrane 
and secreted proteins. Synthesised PrP
C contains a specific N-terminal signal 
peptide (NSP) and a C-terminal hydrophobic GPI anchor sequence (Fig. 1A), 
which are both responsible for co- or post-translational PrP
C translocation into the 
rough endoplasmic reticulum (ER), wherefrom PrP
C transits the Golgi on its way to 
the cell surface (Harris, 2003). During PrP maturation in the ER, PrP
C is subjected 
to several post-translational modifications, including cleavage of the N-terminal 
signal peptide, addition of N-linked oligosaccharide chains (see Fig. 1), formation 
of a single disulphide bond, and attachment of the GPI anchor following cleavage 
of the GPI sequence (Haraguchi et al., 1989; Stahl et al., 1987; Turk et al., 1988). 
The N-linked oligosaccharide chains added within the ER are subsequently 
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modified in the Golgi to yield complex-type chains that contain sialic acid and are 
resistant to endoglycosidase H, but sensitive to Peptide N-glycosidase F 
(PNGaseF). The majority of PrP
C is found in detergent-resistant raft domains on 
the cell surface (Gorodinsky and Harris, 1995; Naslavsky et al., 1997; Vey et al., 
1996). After delivery of PrP
C to the cell surface not all PrP
C molecules remain 
there. Some PrP
C molecules constitutively cycle between the plasma membrane 
and the endocytic compartment (Shyng et al., 1993). Kinetics analysis 
demonstrates that PrP
C molecules cycle through the cell with a transit time of ~60 
min. In the process, internalised PrP
C co-localises with different endosomal 
markers (Magalhaes et al., 2002). The endocytic recycling pathway is of interest 
concerning the prion generation, since the initial steps in the conversion of PrP
C 
into PrP
Sc may take place on the plasma membrane or following internalisation of 
PrP
C (Borchelt et al., 1992; Caughey and Raymond, 1991). 
2.2.3 Putative functions of PrP
C 
While the exact function of the cellular prion protein (PrP
C) is still unclear, there are 
several references due to increasing knowledge on the localisation and interaction 
of PrP
C with other molecules. The reported putative functions include e.g. 
antioxidant properties (Brown et al., 1997c; Brown et al., 1999; Sakudo et al., 
2005a; Senator et al., 2004; Wong et al., 2001), regulatory activity in copper 
metabolism (Brown et al., 1997a; Korte et al., 2003; Varela-Nallar et al., 2006; 
Vassallo and Herms, 2003), neuronal differentiation (Chen et al., 2003; Mouillet-
Richard et al., 1999; Mouillet-Richard et al., 2000; Sales et al., 2002; Steele et al., 
2006), neuroprotective signalling and synaptic function (Collinge et al., 1994; 
Criado et al., 2005; Maglio et al., 2006; Re et al., 2006; Whittington et al., 1995). 
The latter is interesting in terms of the in vivo situation. PrP
C was found in 
presynaptical nerve terminals, synapses in the brain and neuromuscular junctions 
(Brown, 2001; Fournier et al., 1995; Fournier et al., 2000; Haeberle et al., 2000; 
Herms et al., 1999; Sales et al., 1998). Furthermore, PrP
C may be a constituent of 
the synaptic vesicle membrane, since the PrP
C interacting protein synapsin I is 
associated with small synaptic vesicles (Spielhaupter and Schatzl, 2001) and PrP
C 
co-localises with the presynaptic vesicle protein synapthophysin (Fournier et al., 
1995). PrP
C affects the neurotransmitter release via synaptic vesicles as shown for 
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acetylcholine in neuromuscular junction (Re et al., 2006). This would suggest a 
role in the recycling of the vesicles or a more direct role in the synaptic activity. 
The latter has been substantiated by some electrophysiological studies conducted 
in mice devoid of PrP
C, which exhibit weakened GABAA-mediated fast inhibition 
(Collinge et al., 1994) and impaired long-term potentiation (Collinge et al., 1994; 
Criado et al., 2005; Maglio et al., 2006; Whittington et al., 1995). Recombinant PrP 
induces rapid polarisation and development of synapses in embryonic rat 
hippocampal neurons (Kanaani et al., 2005). In vivo accumulation of PrP deposits 
correlates with abnormal synaptic protein expression in the cerebellum of CJD 
brains (Ferrer, 2002), and scrapie-infected mice showed a loss of synapses 
associated with abnormal PrP precedes (Jeffrey et al., 2000), intrinsic dysfunction 
of cortical and hippocampal neurons (Jefferys et al., 1994) and altered properties 
of the membrane and synapses (Johnston et al., 1997). In summary, it seems that 
PrP
C is not required for most vital synaptic functions, but appears to be important 
for the fine-tuning of neuronal function. The other putative functions of PrP
C 
mentioned above are closely associated with its synaptic function. PrP
C binds 
copper via histidines in the octarepeat region and could regulate the copper 
concentration in the synaptic region of neurons and decrease oxidative stress in 
synapses (Herms et al., 1999; Kretzschmar et al., 2000; Morot-Gaudry-Talarmain 
et al., 2003). The latter anti-oxidative activity of PrP
C has been shown i.a. as 
copper/zinc-dependent superoxid dismutase activity (Brown et al., 1997b; Brown 
et al., 1999; Brown and Besinger, 1998; Rachidi et al., 2003; Sakudo et al., 
2005b). Signalling function of PrP
C has been demonstrated by the activation of the 
non-receptor tyrosine kinase fyn (Kanaani et al., 2005; Mouillet-Richard et al., 
2000; Santuccione et al., 2005), which is enriched in brain synaptosomes and has 
been implicated in long term potentiation (Grant et al., 1992) - a further cellular 
pathway through which PrP
C influences the synaptic function. 
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2.3 Neurotoxicity of pathological prion protein 
2.3.1 PrP
Sc and neurotoxicity 
Neuronal cell loss is a hallmark of prion diseases. Several studies in humans and 
in mice models of diverse types of prion diseases indicate that neuronal 
dysfunction and cell death occur through apoptosis, i.e. observed as nuclear DNA 
condensation and fragmentation as well as caspase-3 activation (Chiesa et al., 
2000; Dorandeu et al., 1998; Ferrer, 1999; Giese et al., 1995; Gray et al., 1999; 
Lucassen et al., 1995). A key area of controversy in the field is the toxicity of the 
disease-associated isoform PrP
Sc itself. Although PrP
Sc is associated with the 
pathology and infectivity of prion diseases, the link between PrP
Sc and 
neurotoxicity is unclear. PrP
C conversion to PrP
Sc could cause neurotoxicity 
through the loss of the normal function of PrP
C. Compelling evidence for 
cytotoxicity of PrP
Sc are: i) PrP
Sc accumulation in the brain is a hallmark of TSEs, 
ii) PrP derived peptides e.g. PrP106-126 and PrP82-146 with PrP
Sc-like 
characteristics including high β-sheet content, amyloid fibrilar structure and 
detergent insolubility are toxic in vitro and in vivo (Bahadi et al., 2003; Bergstrom 
et al., 2005; Carimalo et al., 2005; Ferreiro et al., 2006; Forloni et al., 1993; 
Salmona  et al., 2003). iii) there is a good temporal correlation between the 
accumulation of PrP
Sc and the appearance of pathology and clinical symptoms. 
However, a lot of results using transgenic animal models argue against such a 
simple relationship between PrP
Sc accumulation and neurodegeneration: i) 
Neuronal degeneration was observed in the absence of detectable PrP
Sc or 
neuronal damage was not detected despite of high levels of PrP
Sc (Chesebro et 
al., 2005; Chiesa and Harris, 2001; Ersdal et al., 2005; Hill and Collinge, 2003). ii) 
PrP knock out animals do not develop neuropathological and phenotypic 
alterations similar to TSE-affected animals (Bueler et al., 1993; Manson et al., 
1994; Weissmann and Flechsig, 2003). Indeed, adaptive mechanisms during 
neurodevelopment might compensate the loss of PrP
C function, masking any 
phenotype, whereas the loss of PrP
C function in the adult CNS might be 
deleterious. However, it has been demonstrated that PrP
C depletion in the post-
mitotic neurons of adult mice also results in healthy animals with no detectable 
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neuronal cell loss (Mallucci et al., 2002), which also suggests that the loss PrP
C 
function may not be the trigger for neurodegeneration. And iii) host PrP
C 
expression is necessary for cytotoxicity, since PrP
Sc itself is not directly toxic to 
PrP
0/0 neurons (Brandner et al., 1996a; Bueler et al., 1992). Thereby, PrP
Sc 
cytotoxicity is only observed in neurons expressing plasma membrane anchored 
PrP
C on their cell surface (Chesebro et al., 2005). Additionally, it has been shown 
that depletion of PrP
C in conditional PrP knockout mice after prion infection not 
only stops the development of neuronal damage but also reverses the pathology 
(Mallucci et al., 2003). Hence, PrP
C is an indispensable substrate to elicit disease 
in the brain, and deposition of prions alone does not support neurodegeneration. 
These findings have kindled a series of further questions on the mechanisms of 
brain damage in TSEs. So far, it has been postulated that the neurotoxic initiator 
might be an abnormal form of the host PrP
C. 
2.3.2 ER-stress and PrP misfolding 
More recently, it has been published that PrP
Sc induces apoptosis in N2a cells by 
activation of the ER-stress response characterised through ER-calcium release, 
up-regulation of ER chaperones and activation of caspase-12 followed by 
caspase-3 activation (Hetz et al., 2003). In support of these observations made in 
vitro, caspase-12 activation and induction of ER-stress inducible chaperones were 
also detected in brains from scrapie-infected mice and humans affected by CJD 
(Hetz et al., 2003; Hetz et al., 2005; Yoo et al., 2002). PrP can interact with several 
ER chaperones including Bip, calnexin and protein disulfide isomerase (PDI) 
(Capellari  et al., 2000; Hetz et al., 2005; Jin et al., 2000). However, no direct 
accumulation of PrP
Sc in the ER has been described in the TSEs, yet. Rather it 
has been postulated that changes in the calcium homeostasis might be the trigger 
for PrP
Sc-mediated ER-stress and apoptosis (Ferreiro et al., 2006; Hetz et al., 
2003; Kristensson et al., 1993; Sandberg et al., 2004; Wong et al., 1996; Yadavalli 
et al., 2004). Severe ER calcium alterations are also reflected in the accumulation 
of misfolded proteins in the ER, because calcium is essential for the proper folding 
of proteins in the ER (Bushmarina et al., 2006; Verkhratsky, 2002; Zhang and 
Kaufman, 2006). Different overexpressed mutant PrPs associated with human 
prion diseases were found to be accumulated in the ER in several cell lines 
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(Campana et al., 2006; Drisaldi et al., 2003; Gu et al., 2003; Negro et al., 2001). 
Furthermore, ER-stress has also been associated with the pathogenesis of other 
neurodegenerative disorders, including Alzheimer disease (AD), Parkinson´s 
disease (PD) and Huntington disease (HD) (Campana et al., 2006; Ferreiro et al., 
2006; Katayama et al., 2004; Lindholm et al., 2006; Ryu et al., 2002; Sherman and 
Goldberg, 2001; Smith et al., 2005) - all characterised by accumulation of 
abnormal proteins mostly found as aggregates in the brain.  
2.4 PrP
C proteolysis and the proteasomal system 
The proteasome is a multi-subunit protease complex located in the cytoplasm and 
nucleus. Mostly, substrates are modified by Ubiquitin-ligases-mediated poly-
ubiquitination followed by ATP-dependent degradation through the 26S 
proteasome (20S core proteasome and 19S regulator). Particularly, under stress 
conditions such as oxidative stress and/or intracellular accumulation of 
malfunctioned and misfolded proteins the proteasome is the major defence system 
in the cell to prevent “waste overload” (Mehlhase and Grune, 2002). As a 
membrane-anchored protein, mature PrP
C is not a natural substrate for the 
proteasomal 20S/26S system. A small percentage (1-5 %) of the internalised 
molecules are proteolytically cleaved near residue 110 in the endosomes, and the 
N- and C-terminal cleavage products are then secreted (Harris et al., 1993; Shyng 
et al., 1993). Some of the membrane-anchored protein is released into the 
extracellular medium by cleavage within the GPI anchor followed by proteolytic 
attack at amino acid 110/111/112 (α-cleavage) by zinc-metalloproteases of the 
desintegrin and metalloprotease (ADAM) family in the brain (Cisse et al., 2005; 
Hooper, 2005; Jimenez-Huete et al., 1998; Vincent et al., 2001). 
Analysis of proteasome-dependent PrP
C proteolysis revealed that the half life or 
maturation kinetics of wild type-PrP (wt-PrP) or two different mutant PrPs (PG14 
and D177N) were unaffected by treatment with specific proteasome inhibitors PSI1 
and lactacystin in CHO cells (Drisaldi et al., 2003). In contrast, mutant PrP 
associated with GSS can be rapidly degraded (half life 10 min) in a cell culture 
model (Zanusso et al., 1999). Following proteasome inhibition with lactacystin, the 
protein accumulates and forms aggregates in the ER, Golgi apparatus, and 
8 Introduction 
nucleus. In the absence of proteasome inhibition, the mutant PrP does not form 
aggregates, suggesting that impairment of the proteasome system may also be 
involved in pathogenesis of the human disease (Zanusso et al., 1999). 
2.5 Cytosolic PrP  
Secretory or membrane proteins are correctly folded and post-translationally 
modified in the ER lumen by ER chaperones and supporting calcium ions. 
However, a small portion of misfolded or incorrectly modified proteins retains in the 
ER and is subjected to a quality control process by which they are retro-
translocated into the cytoplasm and degraded by the proteasome, a process 
named ER-associated degradation (ERAD) (Bonifacino and Weissman, 1998; Tsai 
et al., 2002). ER chaperones, like Bip, are implicated in the process of recognition 
for the proteasomal degradation. This mechanism is  intended to ensure that 
abnormally folded proteins, or those that are not properly modified or assembled 
into multi-subunit complexes, do not reach the plasma membrane where they 
might cause cellular damage.  
In the case of PrP
C around 10 % of translated PrP
C appears to be retro-
translocated from ER into the cytosol (Yedidia et al., 2001). Such cytosolic PrP 
(Cy-PrP) might be characterised by cleaved NSP and GPI anchor sequences. 
When the proteasomal system is impaired by specific inhibitors such as 
epoxomicin or MG132, retro-translocated wild type PrP
C (wt-PrP) or mutant PrP 
accumulates throughout the cytoplasm (Borchelt et al., 1990; Ma and Lindquist, 
2001; Ma and Lindquist, 2002a; Wang et al., 2005; Yedidia et al., 2001). In 
transfected CHO and PC12 cells expressing PrP from the cytomegalovirus (CMV) 
promoter, proteasome inhibitors induced accumulation of a non-glycosylated PrP 
form in the cytosolic environment. However, this PrP contained the N-terminal 
signal peptide, indicating that it originated from abortive translocation rather than 
retrograde transport from ER lumen.  
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Fig. 2  Schematic view of maturation of membrane proteins and ER-associated degradation 
pathway of misfolded forms. Proteins are co-translationally imported into the ER lumen followed by 
cleavage of the NSPs and different post-translational modifications such as N-linked glycosylation. 
Correctly folded and modified proteins are transported to the Golgi for final maturation. A small 
portion of the protein is misfolded or wrongly modified. This is a signal for the ER quality control 
system to promote their retro-translocation to the cytosol followed by proteasome-mediated 
degradation. 
Otherwise, it has been shown that proteasome inhibition failed to cause PrP 
accumulation in the cytoplasm in cells expressing endogenous level of PrP and in 
primary neurons from transgenic (tg) mice expressing PrP
C from the endogenous 
promoter (Drisaldi et al., 2003). Thus, it has been proposed that the occurrence of 
PrP in the cytosol is dependent on its expression level and CMV-driven PrP 
overexpression saturates the translocation machinery. Indeed, proteasome 
inhibitors seem also to induce strong transcription of CMV- driven cDNAs (Biasini 
et al., 2004; Drisaldi et al., 2003). Nevertheless, under physiological conditions the 
possibility remains that low amounts of cytosolic PrP are produced by abortive 
translocation or retro-translocation, and accumulate to a toxic level if not removed 
by the proteasomal system. The level of tolerable Cy-PrP might be also dependent 
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on its structure and binding to cytosolic protective proteins such as heat shock 
proteins (HSPs). 
2.5.1 Cytotoxicity of cytosolic PrP 
The presence of cytosolic PrP suggests that dysfunction of the proteasomal 
machinery during aging could result in the accumulation of cytotoxic PrP 
molecules in the cytoplasm. Recent work has highlighted this novel possible role 
of a dysfunctional proteasome system in the initiation of prion disease. This might 
explain the onset of some cases of sporadic prion diseases. Lindquist and 
colleagues showed that inhibition of the proteasome leads to accumulation of 
cytosolic PrP, which is spontaneously converted into a PK-resistant PrP
Sc-like 
species in a neuronal cell model (Ma and Lindquist, 1999; Ma et al., 2002a). 
Removal of the proteasome inhibitor from the medium did not stop the generation 
of the PrP
Sc-like species suggesting a self-perpetuating process once it has been 
triggered – a characteristic feature of PrP
Sc-replication (see also 2.1). Accordingly, 
it was examined in different cell models whether cytosolic PrP species trigger cell 
death and apoptosis (Fioriti et al., 2005; Ma et al., 2002b; Rane et al., 2004; 
Roucou et al., 2003). However, it remains controversial whether cytosolic PrP is 
cytotoxic at a very low level and in a cell type dependent manner. On one hand 
accumulation of cytosolic PrP in presence of proteasome inhibition is toxic to N2a 
cells but not to COS 1 and mouse NIH3T3 fibroblasts suggesting that cytosolic 
PrP is only toxic to neuronal cell types (Ma et al., 2002b). On the other hand, it is 
assumed that traces of PrP in the cytosol are extremely toxic to neurons and 
responsible for initiation of neurodegeneration in prion disease since low level 
expression of Cy-PrP in vivo induces massive neuronal cell loss in the granular 
layer of the cerebellum (Ma et al., 2002b). The latter is supported by the fact that 
the generation of stably cytosolic PrP-expressing neuronal cell lines failed so far. 
In contrast to these observations, retro-translocated overexpressed wt-PrP, mutant 
PrP and Cy-PrP itself are not toxic to human primary neurons, nor is Cy-PrP toxic 
in two human neuroblastoma cell lines, BE(2)-M17 and SK-N-SH, treated with the 
proteasomal inhibitor epoxomicin (Roucou et al., 2003). Moreover, Cy-PrP 
expression appears to protect human neurons against BAX-mediated cell death as 
previously observed with wt-PrP. N2a cells expressing CMV-driven wt-PrP or 
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mutant PrPs show no altered morphology or viability after exposure to proteasome 
inhibitors (Fioriti et al., 2005). Rather, PrP overexpression appears to have a 
protective effect under such conditions. Furthermore, neurons in the forebrain 
tolerate higher expression levels of Cy-PrP as granular cerebellar neurons in vivo 
(Wang et al., 2006). Cytotoxic potential of Cy-PrP might be also dependent on the 
interaction with other cytosolic proteins. As published currently, Cy-PrP-induced 
apoptosis after proteasome inhibition in human SH-SY5Y neuroblastoma cells 
involves coaggregation of Cy-PrP with anti-apoptotic Bcl2 (Rambold et al., 2006). 
Further prominent candidates are members of the heat shock protein (Hsp) family 
that could control or influence folding reaction to a PrP
Sc-like structure. Generally, 
chaperones are potent suppressors of neurodegeneration in vivo (Nollen and 
Morimoto, 2002; Tanaka et al., 2002; Tidwell et al., 2004). After proteasome 
inhibition retro-translocated Cy-PrP forms aggregates, often in association with 
Hsc70 in an aggresome-like state (Ma et al., 2001). The expression level of Hsps 
varies in normal and scrapie-infected cells and brain tissue (Belay and Brown, 
2006; Foster et al., 1995; Guzhova et al., 2001; Manzerra and Brown, 1996; 
Prusiner, 1998; Tanaka et al., 2002; Tatzelt et al., 1995; Voisin et al., 1996) as well 
as in the different neuronal cell subtypes in the brain in CJD (Kovacs et al., 2001), 
which might influence the cytotoxicity of Cy-PrP in vitro and in vivo.   
Currently, no complete model exists to explain all these controversial data and it is 
not certain whether cytosolic occurring PrP is toxic per se for neurons or whether 
the whole process of impaired ERAD is necessary to induce cytotoxicity (kinetics 
of ER translocation, ER-stress-mediated apoptosis and involved chaperones). 
Nevertheless, different neuronal cell types might tolerate different distinct amounts 
of cytosolic PrP by a currently unknown mechanism. 
2.6 Ecdysone-inducible expression system 
To clarify the cytotoxic potential of Cy-PrP to neuronal cells, an inducible rather 
than a constitutive expression system was sought to conduct the in vitro 
neurotoxicity experiments. The most widely used Tet-On/Tet-OFF inducible 
expression system (Baron et al., 1997; Gossen and Bujard, 1992), in which gene 
expression depends on tetracycline, was not adapted in this study due to major 
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concerns about reported interactions of PrP with tetracycline (Forloni et al., 2002; 
Tagliavini  et al., 2000). Thus, the ecdysone-inducible dual vector system 
(Invitrogen) was used, in which gene expression can be regulated through the 
addition of the ecdysone ponasterone A (PonA), a natural glucocorticoid 
originating from insects (No et al., 1996; Saez et al., 2000). The vector pVgRXR 
expresses both VgEcR and RXR, which bind together to form the modified 
heterodimeric nuclear glucocorticoid receptor VgRXR as transactivator (Fig. 3). 
The gene of interest is cloned into the multiple cloning site of the pIND vector 
containing the glucocorticoid receptor recognition element (E/GRE), which is 
bound by the transactivator VgRXR.  
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Fig.  3  Regulation of transcription using the ecdysone-inducible system. The synthetic 
receptor VgEcR is a fusion of the ligand-binding and dimerisation domain of the Drosophila 
ecdysone receptor (EcR), the DNA-binding domain of the glucocorticoid receptor (GR), and the 
transcriptional activation domain of herpes simplex virus (HSV) VP16. VgEcR and human retinoid 
X receptor α (RXR) bind as a heterodimer to five copies of the E/GRE recognition sequence (5× 
E/GRE), which are located upstream of the minimal heat shock promoter (P ∆mHSP). The E/GRE 
recognition sequence consists of inverted half-site recognition elements for the RXR and the GR 
DNA-binding domains. In the absence of PonA (the inducer), the promoter is tightly repressed by 
co-repressors. When PonA binds to VgEcR, the co-repressors are released, co-activators are 
recruited, and the complex becomes transcriptionally active. 
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A comparison of tetracycline-based and ecdysone-based inducible systems 
reveals that the ecdysone regulatory system exhibits lower basal activity and 
higher inducibility in vitro and in vivo (Galimi et al., 2005; Meyer-Ficca et al., 2004; 
No et al., 1996; Senner et al., 2001). The latter is extremely target-dependent and 
has to be verified for each target protein. Since ecdysone administration has no 
apparent effect on mammalian cells, its use for regulating genes should be 
excellent for transient inducible expression of eventually toxic genes or extremely 
regulative genes in cell cultures, transgenic mice and for gene therapy. 
 
14 Introduction 
2.7 Objectives 
The truncated cytosolic form (Cy-PrP) of PrP
C is in vivo toxic to neurons in the 
cerebellum of transgenic Cy-PrP-expressing mice and is leading to clinical 
symptoms like in prion disease. In vitro Cy-PrP toxicity is controversial discussed 
and the mechanisms for selective observed toxicity are unknown. To analyse the 
cytotoxic potential of Cy-PrP and the underlying mechanisms, in vitro neuronal cell 
models were established to analyse effects of transiently and stably expressed Cy-
PrP on N2a cells. Thereby, a set of different experiments were performed to 
address the following questions: 
 
1.  Examination of the cytotoxic potential of inducibly expressed Cy-PrP using 
different viability and apoptosis assays  
2.  Role of the proteasome in Cy-PrP-mediated cytotoxicity 
3.  Analysis of Cy-PrP stability and proteolysis to determine Cy-PrP properties 
in comparison to PrP
Sc 
4. Subcellular distribution of Cy-PrP by co-localisation with different cell 
compartment markers and chaperones 
5.  Generation of stably Cy-PrP expressing cells as cellular models for further 
investigations of the Cy-PrP metabolism and its effects on cell signalling 
and survival 
 
 
 
15 Materials and Methods 
3  Materials and Methods 
3.1 Materials and chemicals 
3.1.1 Materials and equipments 
Absorption and fluorescence in viability assays, proteasome and caspase-3 
activity were measured in the „GENios plus“ platereader (Tecan). For fluorescence 
experiments, samples were analysed in black 96 well plates (Nunc, #137101). 
Flasks from Greiner and dishes from Nunc were used for cell cultivation. DNA 
concentration was determined by measuring DNA absorption in the “GeneQuant 
pro” photometer (Amersham Pharmacia). 
 
Materials for semi-dry immunoblotting: 
0.2 µm Protran BA-83 nitrocellulose    Schleicher and Schuell, #10401396 
0.2 µm Optitran BA-S 83 nitrocellulose    Schleicher and Schuell, #10439396 
Blotpaper Protean Xl size        BioRad, #170-3968 
Blotpaper xi size            BioRad, #170-3969 
 
3.1.2 Chemicals 
All chemical used for molecular and biochemical methods are listed alphabetically 
as follows: 
 
Name Company  Cat.-No. 
acetic acid  Roth  T179.1 
agarose Invitrogen  15510-027 
ampicillin Roth  K029.2 
7-amino-4-methylcoumarin (AMC)  BACHEM Q-1025 
aprotinin   Roth  A162.2 
ATP-Mg Sigma  A-9187 
deoxycholat   Sigma  D-6750 
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bis-benzimid (Hoechst)  Sigma   B2261 
boric acid  Sigma  B-6768 
bovine serum albumin (BSA)  Sigma  A7906 
dNTP  New England Biolabs  N0446S 
dimethylsulfoxide (DMSO)  Sigma  D-2650 
dithiothreitol (DTT)   Sigma  D-9163 
ethanol Roth  5054.1 
ethidium bromide  Sigma  E-8751 
epoxomicin Calbiochem  324800 
Ficoll type 400  Amersham pharmacia  17-0300-10 
geniticin Invitrogen  10131-027 
glycine (99 %)  Sigma  G-5516 
glycerol (99 %)  Sigma  G-8898 
isopropanol Roth 9866.1 
leupeptin   Sigma   L8511 
methanol Roth  4627.5 
3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT)
Roth 4022.1 
NaCl   Sigma  S7653 
NP40 10%   Sigma   74388 
phenol-chloroform Roth  A156.1 
ponasterone A   Sigma  P-3490 
puromycin   Sigma  P9620 
SDS (Lauryl sulfate)  Sigma  L-4390 
suc-LLVY-AMC   Calbiochem  539142 
sucrose Fluka  84099 
Tris-HCl Roth    9090.1 
Tween 20   BioRad  170-6531 
zeocin   Invitrogen  R250-01 
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3.1.3 Enzymes 
All restriction enzymes and corresponding buffers were purchased from New 
England Biolabs and used according to the manufacturer’s instructions.  
 
 
Name Company  Cat.-No. 
Ampli-Taq  Roche Applied Biosystems  N8080152 
PNGaseF   Sigma   G5166 
Proteinase K  Roche Applied Biosystem  1 429 868 
T4 DNA Ligase  New England Biolabs  M0202S 
 
3.1.4 Cells and media  
All media (fluid and plates) as well as trypsin (0.25 % trypsin in PBS, 1 mM EDTA) 
and PBS solutions were prepared by colleagues of the media and reagent facility 
at the Paul-Ehrlich-Institut according to the generally used receipts (Sambrook and 
Russel, 2001). SOC medium for bacterial transformations was purchased from 
Invitrogen (#15544034). 
 
For cultivation of eukaryotic cells DMEM/Glutamax medium (Gibco, #21885-108) 
and Optimem medium (Gibco, #31985-047) were used. Media were supplemented 
with fetal bovine serum (Gibco, #10270-106, Lot 40G9943K). Horse serum (Gibco, 
#26050-070) was used as blocking reagent for immunoblotting. 
The following cell lines were used: 
N2a  murine neuroblastoma cell line (ATCC: CCL-131) 
HEK293T  human embryonal kidney cell line expressing the large T antigen 
(ATCC: CRL-11268) 
PrP
0/0 PrP
C knock out (Zurich I) cerebellar neuronal precursor cell line (gift 
by D. Rossi, Mailand) 
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3.1.5 Kits 
All kits were used according to the manufacturer’s directions. 
 
Table 1   Alphabetical order of the used kits 
Name Company  Cat.No  Application 
BCA Kit  Pierce  23227  Protein concentration 
CytoTox-one Kit  Promega  G7890  Cytotoxicity assay (LDH) 
EndoFree Plasmid Maxi Kit  Qiagen  12362 
Plasmid DNA 
preparation 
QIAfilter Plasmid Midi Kit  Qiagen  12243 
Plasmid DNA 
preparation 
Qiaprep Spin Miniprep Kit  Qiagen  27106 
Plasmid DNA 
preparation 
QIAquick gel extraction Kit  Qiagen  28704  DNA gel extraction 
QIAquick PCR purification Kit  Qiagen  28106 
DNA fragment 
purification 
Re-Blot Plus Kit  Chemicon  2500-S  Western striping reagent 
 
3.1.6 Antibodies 
Antibodies for immunoblotting (IB), immunoprecipitation (IP), immunofluorescence 
(IF) and FACS analyses were used as shown in Table 2 
  
Table 2   Summary of all used antibodies and their application 
Primary antibody  Origin  Dilution 
IB/IP 
Dilution 
IF/FACS 
Company/ 
Cat.No. 
β-actin  mouse IgG1 1:40.000    Sigma/ A5441 
Calnexin Rabbit  1:2.000    Stressgen/  SPA-860 
EEA1  rabbit     1:300  Calbiochem/ 324610 
GAPDH  mouse IgG  1:20.000    Abcam/ ab9484 
Giantin Rabbit    1:500  Convance/  PRB-114C 
Hsc70  rat IgG1    1:300  QED/ 11042-200 
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Hsc70  Goat  1:5.000    Santa Cruz/ Sc-1059 
PDI  mouse IgG1   1:300  QED/ 11080-50 
3F4 PrP(hu) 
mouse 
IgG2a 
1:2-5.000 1:250  Chemicon/  MAB1562 
SAF32 PrP 
mouse 
IgG2b   
1:100   Cayman/  189720 
6H4 PrP  mouse IgG1 1:500    Prionics/ 01-010 
R340 PrP  Rabbit  1:500    gift from Aguzzi  
20Sα5   Rabbit  1:1.000    Affinity/ ABR-
PA11962C-100 
Isotype IgG2a 
mouse 
IgG2a  
 1:250  Becton Dickenson, 
#553454 
Isotype IgG1  mouse IgG1    1:300 
Becton Dickenson, 
#553447 
 
secondary 
antibody  Origin  Dilution 
IB 
Dilution 
IF 
Company/ 
Cat.No. 
α-mouse-HRP  Goat  1: 15.000    Zytomed/ 81-6720 
α-rabbit-HRP Donkey  1:20.000    Amersham Pharmacia/ 
NA9340 
α-goat-HRP Donkey  1:10.000   Dianova/  705-035-147 
α-mouse-A594 Goat    1:1.000  Molecular Probes/ A-
21135 
α-mouse-A488 Goat    1:500 Molecular Probes/ A-
21121 
α-rabbit-A488 Goat    1:500  Molecular Probes/ A-
11070 
α-rat-A488 Goat    1:500  Molecular Probes/ A-
11006 
α-mouse-RPE Goat    1:1.000 
(FACS) 
Dako/ 115-116-171 
 
3.2 Molecular biology 
3.2.1 Plasmids 
The plasmids pIND and pcDNA3.1 were used for generation of Cy-PrP and PM-
PrP encoding vectors. Plasmid pVgRXR is part of the ecdysone-inducible 
expression system and encodes the transactivator protein VgRXR. The linearised 
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plasmid pGEM-Teasy was used for intermediate cloning steps of PCR-fragments 
harbouring single adenosine (A) overhangs via T/A-cloning.  
 
Name 
Resistance gene 
bacteria/mammalian 
 
Company 
pGEM-Teasy Ampicillin  Promega 
pUC18  Ampicillin  gift from M. Hamdorff 
pVgRXR zeocin/zeocin Invitrogen 
pIND ampicillin/geniticin  Invitrogen 
pcDNA3.1 (+)  ampicillin/geniticin  Invitrogen 
 
To ensure correctly inserted transgenic sequences, plasmid DNA was sent to 
MWG for sequencing. 
3.2.2 Construction of vectors encoding transgene PrPs 
Full length PrP (PM-PrP) and cytosolic PrP (Cy-PrP) were cloned into the 
ecdysone-inducible vector pIND (Invitrogen) for transient experiments and into 
pcDNA3.1 (Promega) for generation of stable cell lines. From genomic DNA of 
MH2M transgenic mice, the open reading frame encoding the mouse-hamster-
mouse chimeric PrP was amplified by PCR and cloned into a pPrPcDNA vector 
generating the pPrPcDNAMH2M plasmid (supplied by G. Barenco, unpublished), 
which served as template for the following cloning steps. DNA-fragments encoding 
Cy-PrP and PM-PrP were amplified by PCR using the primers Cy-PrP-for/-rev and 
F1-for/F2-rev containing the restriction sites BamHI and EcoRI (see table 3). 
Amplified PrP fragments were ligated into linearised pGEM-Teasy plasmid 
(Promega) according to the manufactures protocol. From pGEM-Teasy, Cy-PrP 
and PM-PrP fragments were removed through BamHI-EcoRI restriction followed 
by ligation into BamHI/EcoRI digested target vectors pIND and pcDNA3.1. 
Sequencing (MWG Biotech) of pIND and pcDNA3.1 using the primers pIND-for/-
rev and T7-for/BGH-rev(pCR3.1) (see table 3) verified correct cloning of Cy-PrP 
and PM-PrP into pIND and pcDNA3.1 vectors.  
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3.2.3 Polymerase chain reaction  
In the polymerase chain reaction (PCR), DNA-dependent DNA-polymerases 
amplify specific DNA sequences of different origins, such as plasmid, genomic or 
complementary DNA bordered by two primer sequences (Mullis and Faloona, 
1987; Saiki et al., 1985). In this study Taq-polymerase (Roche Applied 
Biosystems) isolated from Thermophilus aquaticus was used, which shows a 
temperature optimum of 72 °C. One complete PCR cycle contains a DNA 
denaturation step at 94 °C followed by primer annealing to the single stranded 
DNA template. The annealing temperature (TD) is adjusted according to length 
and composition of the DNA template. The TD can be calculated roughly 
corresponding to the Wallace rule (Suggs et al., 1981) as follows: TD = 4 x (G+C) 
+ 2 x (A+T) or tested by temperature gradient PCR as done in this study. DNA 
elongation is performed at 70-75 °C corresponding to the Taq-polymerase activity 
optimum. The length of the template determines the elongation time, since Taq-
polymerase has an amplification activity of approximately 1 kb DNA/min. Multi-
repeating of the cycle leads to amplification of the DNA-fragment in an exponential 
manner. For amplification of PrP sequences the following PCR mix (50 µl) was 
used: 
 
1x PCR buffer (20 mM Tris/HCl, pH 7.5; 100 mM KCl; 1.5 mM MgCl2; 1 mM DTT; 
0.1 mM EDTA, 0.5 % Tween 20; 0.5 % Nonidet P40; 0.01 % gelatine) 
0.5 pmol/µl of each primer  
300 µM dNTPs 
2.5 units Ampli-Taq  
10-20 ng template (plasmid DNA)  
 
PCR was performed at following conditions: 
94 °C 2.5 min 
94 °C 30 sec 
gradient 45-65 °C 45 sec  29 cycles 
72 °C 45 sec 
72 °C 4 min; subsequent cool down to 4 °C 
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All PCR reactions were performed in a “PTC200” Peltier thermal cycler (MJ 
Research). Analysis of PCR fragments were performed in 1 % agarose gel 
followed by purification of the PCR sample using PCR purification kit (Qiagen). 
 
Colony-PCR was used to identify bacterial clones containing the transgene DNA 
fragments. E.coli colonies were picked and transformed in PCR tubes followed by 
PCR as described above except the annealing temperature was 54 °C. Using the 
designed primers M13-for/-rev, pIND-for/rev and T7-for/ BGH-rev(pCR3.1) (see 
table 3) allowed testing of the right orientation of integrated fragments in the 
vectors pGEM-Teasy, pIND and pcDNA3.1. 
3.2.4 Oligonucleotides 
Table 3   Sequences of used oligonucleotides 
Name 5´-sequence-3´ 
F1-for ATCGGGATCCGCCACCATGGCGAACCTTGGCTACTGG 
F2-rev TGCGGAATTCACTCACTCATCCCACGATCAGGAAGATGAGG
Cy-PrP-for ATCGGGATCCGCCACCATGAAAAAGCGGCCAAAGC 
Cy-PrP-rev TGCGGAATTCACTCACTCAGCTGGATCTTCTCCCGTCG 
M13-for GTAAAACGACGGCCAG   
M13-rev CAGGAAACAGCTATGAC 
pIND-for AGAAAGAAGAACTCACACACAGC 
pIND-rev AACTAGAAGGCACAGTCGAGG 
T7-for TAATACGACTCACTATAGGG 
BGH-rev(pCR3.1) TAGAAGGCACAGTCGAGG 
 
3.2.5 Agarose gel electrophoresis 
For analytical and preparative purposes, DNA molecules were separated by 
agarose gel electrophoresis. Negatively charged DNA molecules migrate with 
different velocity dependent on their size through such a gel upon application of 
electric current. For DNA molecules with a size of 0.5-14 kb 1-2 % agarose gels 
were produced by dissolving agarose in Tris-acetate-EDTA (TAE) buffer by 
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heating in a microwave oven. Cooled agarose solution was supplemented with 0.5 
µg/ml ethidium bromide for DNA labelling. DNA solution was mixed with 1/6 
loading buffer and separated on gel at 120 V. 100 bp-, 1 kb- and 2-log-DNA 
ladders (New England Biolabs) served as DNA size standard. For preparative 
agarose gel electrophoresis, DNA fragments were cut out and purified using 
QIAquick gelextraction kit (Qiagen). 
  
TAE buffer      6 x loading buffer : 
40 mM Tris-acetate       0.25 % bromphenolblue 
1  mM  EDTA      0.25  %  xylene-cyanol  FF 
adjusted to pH 7.5        15 % Ficoll (typ400, Pharmacia) 
 
3.2.6 Restriction and ligation  
DNA molecules were digested with type II restriction endonucleases to provide 
DNA molecules for ligation or to analyse vectors for the correct transgene 
integration. All DNA restrictions were performed using commercially available 
restriction endonucleases from New England Biolabs (NEB, Schwalbach, 
Germany) according to the manufacturer’s instructions. Ligation of two double 
stranded nucleic acid molecules was achieved by usage of T4 DNA ligase, which 
catalyses the formation of phosphodiester-bonds between the fragments, under 
consumption of ATP. 50-100 ng DNA with molar ratio of backbone to insert 1:3 
were incubated with 100 U T4 DNA ligase (NEB) in ligase buffer (50 mM Tris-HCl 
pH 7.5, 10 mM MgCl2, 10 mM DTT, 1 mM ATP, 25 µg /ml BSA) with end volume of 
20 µl at 4 °C overnight. 
3.2.7 DNA purification 
3.2.7.1  PCR purification kit 
DNA from restriction reactions or PCR samples were purified using the “QIAquick 
PCR purification kit” (Qiagen) according to the manufacturer’s instructions. 
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Thereby, DNA molecules bind to silica-gel membrane. After washing, DNA was 
eluted with bidestillated water. 
3.2.7.2  Phenol extraction and DNA precipitation  
Phenol extraction allows removal of proteins from DNA/RNA solution (Sambrook 
et al., 2001). The DNA solution was filled up with water to 200 µl and mixed step 
by step 1:1 with phenol (pH 8.0), phenol-chlorophorm-isoamylalcohol (25:24:1, v/v) 
and chlorophorm. In between, each sample was centrifuged for 1 min at 16 100 x 
g and the aqueous phase was transferred into a new tube. DNA from the aqueous 
phase recovered after the last chlorophorm extraction was precipitated with 2.5 
fold volume ethanol in presence of 0.3 M Na-acetate (pH 5.2) for 1 h at -80 °C or 
with 0.7 volume isopropanol at room temperature for 5 minutes. Precipitated DNA 
was centrifuged at 16100 x g at 4 °C for 30 min, washed twice with 70 % ethanol, 
dried and suspended in 50 µl of bidestillated water.  
3.2.8 Photometric determination of DNA concentration 
DNA concentration was determined using ultraviolet absorption spectroscopy. 
Absorption at 260 nm (A260) and 280 nm (A280) was measured and DNA 
concentration was calculated as follows:  
c [µg/ml] = A260 x 50 x DF    
DF = dilution factor 
50 = specific absorption coefficient for dsDNA 
Absorption of 1.0 corresponds to 50 µg/ml double stranded DNA (Sambrook et al., 
2001). The ratio A260/A280 served as value DNA purity. Pure DNA samples showed 
ratios of 1.8-2.0.  
3.2.9 Working with bacteria 
3.2.9.1  Cultivation of bacteria 
E. coli DH5α were grown as suspension culture in LB-medium (10 g/l peptone, 5 
g/l yeast extract, 10 g/l NaCl pH 7.0 with NaOH) at 200 rpm or on LB agar plates 
(2 % agar in LB-medium) at 37°C overnight. Selection of transformed bacteria was 
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achieved by adding different antibiotics corresponding to the plasmid resistance 
genes (50 µg/ml ampicillin, 25 µg/ml zeocin). Identification of positive bacteria 
clones of pGEM-Teasy transformants were analysed by blue/white screening after 
cultivation on LB-agar plates containing 50 µg/ml X-Gal and 10 µg/ml IPTG. For 
long-term storage, 1 ml bacterial suspension was mixed with 1 ml DMSO solution 
(7 % v/v) and transferred to -80°C.      
3.2.9.2  Generation of competent bacteria      
Chemically competent bacteria of the E. coli strain DH5α were produced as 
described by Hanahan (Hanahan et al., 1991). Briefly, 200 ml LB-medium were 
inoculated with 2 ml of E. coli DH5α overnight culture and incubated at 200 rpm 
and 37°C until bacteria achieved the optical density of 0.2-0.3 at 600 nm (OD600). 
Following 10 min incubation on ice, bacteria were centrifuged at 5.000 x g for 10 
min at 4°C and the pellet was suspended in 50 ml of cold 100 mM CaCl2. 
Centrifugation was repeated following 30 min incubation on ice and the pellet was 
suspended in 10 ml of cold 50 mM CaCl2 supplemented with 20 % glycerine. 100 
µl aliquots were frozen immediately in liquid nitrogen and stored at -80 °C.    
3.2.9.3  Transformation of bacteria  
Chemically competent bacteria E. coli DH5α were thawed on ice. 50 µl bacteria 
suspension were mixed with 2-10 µl of ligation reaction or 1 ng pUC18 (as control) 
and incubated for 30 min on ice. Then, bacteria suspension was incubated at 42 
°C for 60 sec and cooled down on ice for 2 min. After addition of 800 µl SOC 
medium bacteria were incubated at 37°C for 1-2 h. 100 – 400 µl transformed 
bacteria were plated on agar plates and cultivated at 37°C overnight.    
3.2.9.4  Plasmid DNA preparation 
Plasmid-DNA isolation and purification was performed using plasmid preparation 
kits (Qiagen) according to the manufacturer’s directions. Briefly, following bacterial 
lyses, the plasmid-DNA bound to an anion exchange column. The column was 
washed and plasmid DNA was eluted by bidestillated water. Plasmid-DNA 
concentration was determined photometrically (3.2.8). To identify correctly ligated 
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plasmid-DNA, 3 ml of bacterial transformants were prepared using Qiagen Mini-kit 
for low-scale plasmid-DNA isolation followed by DNA-restriction analysis and 
DNA-sequencing. Mini preparations were done with 3 ml of an overnight bacterial 
culture using the Mini-kit (Qiagen) to identify the correct ligated and amplified 
plasmid DNAs in optimised restriction analyses. To transfect plasmid-DNA into 
eukaryotic cells, 200 ml of bacterial transformants were prepared using Endo-free 
Maxi kit (Qiagen) for large-scale plasmid-DNA isolation with high purity. These 
purified plasmids were used in transfection experiments with eukaryotic cells.  
3.3 Cell biology and biochemistry 
3.3.1 Cultivation of eukaryotic cells 
All cell lines were cultured in Dulbecco´s Modified Eagles Medium (DMEM; Gibco 
BRL, Eggenstein, Germany) supplemented with glutamax and 10 % fetal calf 
serum (Gibco BRL, Eggenstein, Germany) at 37 °C and 5 % CO2. For transient 
transfection 2 x 10
6 cells were seeded in T75 flasks and incubated for 24 h 
followed by transfection using Lipofectamin 2000 (Invitrogen) according to the 
manufacturer’s directions. Plasmids encoding PM-PrP or Cy-PrP (4 µg) and the 
ecdysone receptor (4 µg) were transfected into N2A cells and 293T cells. After 24 
h PrP expression was induced using 0.5-2 µM PonA (Invitrogen) for different 
periods of time as indicated. To generate stable Cy-PrP expressing cell lines, N2a 
cells were transfected with Cy-PrP or PM-PrP encoding plasmid pcDNA3.1 
(Promega, 8 µg) followed by selection of antibiotic-resistant cell clones using 1 
mg/ml G418 48 h post-transfection. After 3 weeks of antibiotic selection, Cy-PrP- 
and PM-PrP-expressing cell clones were further cultivated in 0.5 mg/ml G418 
containing medium.  
In the case of neuronal PrP
0/0 precursors, 1.4 x 10
6 cells were seeded in 10 cm 
dishes for 24 h and transfected with 24 µg Cy-PrP encoding plasmid pIRES2-puro 
in serum-free Optimem (Promega) using FUGENE transfection reagent 
(DNA:reagent 1:3). After 6 h incubation at 37 °C, FBS was added to a final 
concentration of 10 % and transfection procedure was elongated overnight at 37 
°C followed by medium substitution against DMEM containing 10 % FBS. 
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Selection of antibiotic-resistant cell clones started 48 h post-transfection using 
medium supplemented with 2 µg/ml puromycin and 10 ng/ml basic fibroblast 
growth factor (BFGF, Sigma). Selected stable Cy-PrP-expressing cell clones were 
further cultivated in 1 µg/ml puromycin containing medium.  
3.3.2 Determination of the cell number 
Cells were incubated 1:1 (v/v) with 0.4 % trypan blue solution (Sigma, #T8154) for 
5 min at room temperature and counted in a Neubauer chamber (Fischer, 
#9161078). Trypan blue is able to stain cells with compromised membrane 
integrity. Thus, living and dead cells can be distinguished by uptake of the blue 
dye into dead cells. Only living cells were used for cell number determination. Cell 
numbers were calculated as followed: 
cell no. / 4 (s) x 2 (DF) = X x 10
4 cells/ ml 
s = no. of squares 
DF = dilution factor 
Same cell numbers were seeded for the experiments as indicated. 
3.3.3 Flow cytometry analysis 
To analyse green fluorescence protein (GFP) and PM-PrP expression in N2a and 
293T cells, flow cytometry (FACS) was performed as follows: cells were washed 
with PBS, harvested with PBS containing 1 mM EDTA and centrifuged at 200 x g 
at 4 °C. 10
5 cells were equilibrated in 1 ml FACS buffer (1 % BSA, 5 mM EDTA, 
0.01 % NaN3 in PBS) on ice. After centrifugation at 200 x g and 4 °C, cells were 
suspended in 500 µl FACS buffer and GFP fluorescence was measured with the 
“FACScan” machine (Becton Dickinson). For PM-PrP, cells were suspended in 
100 µl FACS buffer containing 3F4 antibody 1: 1.000 dilution and incubated on ice 
for 30 min followed by washing with 4 ml FACS buffer. Then, cells were incubated 
with mouse-anti-goat-IgG-IR-PE-(Fab2) 1:200 in 100 µl FACS-Puffer 30 min on 
ice, washed twice with FACS buffer and suspended in 500 µl FACS buffer for 
FACS measurement. All measurements were analysed using the “Cell Quest” 
software from Becton Dickinson. 
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3.3.4 Viability assays  
For cell viability analysis, 20.000 cells/well were plated in 96-well plates one day 
after transfection and grown for additional 24 h or 48 h in cell culture medium 
supplemented with 2 µM PonA for transgene induction. Firstly, cell viability was 
quantified by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) method. Briefly, 10 µl of MTT (2 mM) labelling reagent were added to each 
well, and the samples were incubated for 4 h at 37 °C. 100 µl of solubilisation 
mixture (isopropanol/0.04 N HCl) were added to each well, and the samples were 
thoroughly mixed. Absorbance of blue formazan was measured with a plate reader 
at 560 nm. Optimisation of cell counts ensured an OD560 of 0.2-1.0. Secondly, cell 
injury was monitored by measuring lactate dehydrogenase (LDH) release into the 
supernatant by using the CytoTox-one kit (Promega). LDH was assayed by an 
indirect fluorescence measurement of NADH formation during lactate oxidation to 
pyruvate using resazurin, with an excitation wavelength of 535 nm and an 
emission wavelength of 610 nm. For proteasome inhibition epoxomicin was diluted 
in DMSO (1 mM) and added at 50 nM to the culture medium for 16 h prior MTT or 
LDH measurement. 
3.3.5 Caspase-3 activity assay 
Cells transfected with mock plasmid, Cy-PrP or PM-PrP were lysed in 10 mM 
HEPES containing 2 mM EDTA, 0.1 % NP40, 1 mM DTT, 1 mM PMSF, 2 µg/ml 
aprotinin and 2 µg/ml leupeptin for 15 min at 4 °C followed by centrifugation at 
10000 x g. Protein concentration was determined in supernatants by the micro-
BCA assay (Pierce). 150 µg protein of the supernatant were incubated with 50 µM 
caspase-3 specific substrate DMQD-AMC for 60 min at 37 °C in reaction buffer 
(100 mM HEPES, 0.5 mM EDTA and 20 % glycerol) in presence or absence of 10 
mM specific inhibitor AcDEQD-CHO. Caspase-3 mediated release of AMC as 
measured by fluorescence with an excitation wavelength of 380 nm and an 
emission wavelength of 465 nm (same principle as shown in Fig. 6 under 3.3.9) 
Non-specific caspase-3-like activity was calculated by subtraction of fluorescence 
of inhibitor treated samples. Values were normalised as percentage to mock-
transfected cells.  
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3.3.6 Proteinase K digestion 
Cells were lysed in lysis buffer (50 mM Tris pH 7.4, 150 mM NaCl, 0.1 % Triton X-
100, 0.5 % DOC, 1 mM DTT, 2 mM EDTA and 1 µg /ml pepstatin and leupeptin) 
and incubated for 15 min on ice followed by centrifugation step at 10.000 x g for 3 
min. Protein concentration was determined in supernatants by the micro-BCA 
assay (Pierce). Protein concentration was adjusted to 0.6 mg/ml by adding lysis 
buffer. 1 or 10 µg/ml proteinase K (PK, Roche diagnostics) was added to 200 µg 
protein and the volume was adjusted to 100 µl with PBS incubated at 37 °C for 30 
min. Proteinase K activity was stopped by addition of 1 mM Pefablock (Serine 
protease inhibitor, Roche diagnostics) on ice. After 5 min samples were 
centrifuged at 16.000 x g for 45 min at 4 °C, supernatants were discarded and 
pellets were suspended in 20 µl sample buffer (see 3.3.7) followed by 5 min boiling 
at 95 °C. Detection of PK-resistant Cy-PrP was performed by immunoblot using 12 
% SDS-PAGE and 3F4 antibody.   
3.3.7 SDS-PAGE  
Cells were washed with PBS, harvested with PBS containing 1 mM EDTA and 
centrifuged at 200 x g at 4°C. Cells were lysed in lysis buffer (50 mM Tris pH 7.4, 
150 mM NaCl, 0.1 % Triton X-100, 0.5 % DOC and 1 mM DTT) and incubated for 
30 min on ice. Lysates were homogenised by pulling up and down with „Omnifix-F 
1ml“ syringes (Roth, #H999.1) using “0,4 x 22 mm, 27 G ¾” needle (Roth, 
#X133.1) before 10 min centrifugation step at 1.000 x g, Post-nuclear 
supernatants were collected and protein concentration was determined in 
supernatants by micro-BCA assay (Pierce). Equal amounts of protein were 
electrophoretically separated due to their molecular weight in 10 % or 12 % 
polyacrylamide gels (NuPAGE from Invitrogen or self-poured) according to 
Laemmli (Laemmli, 1970). Protein denaturation was achieved by 5 min incubation 
at 95 °C in presence of 5 % β-mercaptoethanol and 5 % SDS added to the sample 
buffer. Discontinuous SDS polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed at 100-200 V with MES buffer (Invitrogen, #NP0002) using precast gels 
or the following running buffer using self cast gels: 
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SDS running buffer (1 l)     4 x sample buffer
36 g glycin            200 mM Tris-HCl pH 6.8 
7.75  g  Tris       400  mM  DTT 
1.25 ml 20 % SDS          20 % SDS 
add 250 ml aqua bidest        40 % glycerol 
       2 0   %   β-mercaptoethanol 
       0.4  %  bromphenolblue 
 
Seeblue 2 plus and MultiMark (both from Invitrogen) were used as protein 
standards.  
3.3.8 Immunoblot analysis 
Electrophoretically separated proteins were transferred onto a 0.2 µm 
nitrocellulose (Schleicher.und Schuell) by semi-dry blotting at 15 V for 20-30 min 
using the “semi-dry cell chamber” from Bio-Rad. To block non-specific binding of 
the antibodies, the membrane was incubated with 10 % horse serum (Gibco) in 
PBS (pH 7.4) containing 0.1 % Tween 20. The blots were incubated with the 
primary antibodies (dilutions see  Table 2, 3.1.6) 3F4 anti-PrP, anti-proteasome 
20S subunit α5 (anti-20Sα), anti-Hsc70, anti-GAPDH, anti-β-actin and anti-
calnexin for 1h at room temperature. For the detection of primary antibodies, 
appropriate peroxidase conjugated secondary antibodies were used (3.1.6,Table 
2) in conjunction with SuperSignal west pico chemiluminescence substrate (Pierce 
Chemical Co., Rockford, Illinois) according to the manufacturer’s directions.  
 
Semi-dry blot buffer:  3.03 g Tris 
14.4 g glycin Æ adjusted to 1 l bidest  
3.3.9 Proteasome activity assay 
Cells were washed twice with PBS, harvested by scraping and lysed in 250 mM 
sucrose, 25 mM HEPES pH 7.8, 10 mM MgCl2 and 1 mM EDTA by repeating 
freezing and thawing cycles. To remove non-lysed cells, nuclei and debris, the 
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lysates were centrifuged at 16.100 x g at 4 °C for 30 min. Supernatants were used 
for activity assays. 
The proteasome has three different catalytic activities promoted by inner ring β1, 
β2- and β5-unit. Thereby, chemotrypsin-like activity appears to play a major role 
and is characterised by cleavage behind LLVY sequence. Thus, AMC-conjugated 
LLVY substrate (LLVY-AMC) was used to determine specific ATP-dependent 
proteasome activity (Fig. 4). Proteasome-mediated cleavage behind the tyrosine 
releases free AMC resulting in fluorescence with an emission wavelength at 460 
nm following excitation at 380 nm. The fluorescence can be observed as blue light 
bands in native proteasome activity gels or was measured at 460 nm in a 
fluorescence plate reader. 
 
LLVY-
LLVY
AMC AMC
proteasome
LLVY-
LLVY
AMC AMC
proteasome
Fig. 4 
 
 
Principle for measurement of proteasome activity. Proteasome peptide substrate LLVY 
is conjugated with fluorophor aminomethylcumarin (AMC). Bound AMC does not emit fluorescence. 
Proteasome-mediated cleavage behind the tyrosine releases free AMC, which emits light at 460 
nm following excitation at 380 nm. 
3.3.9.1  Native gel electrophoresis 
200 µg protein of supernatant were loaded on a non-denaturating 4.5 % Tris-
Borat-EDTA gel (supplemented with 2.5 % sucrose) and electrophoretically 
separated at 4 °C and 50 V for 20 h. The native gel was incubated in developing 
buffer (50 mM Tris pH 7.8, 25 mM KCl, 10 mM NaCl, 1.1 mM MgCL2, 0.1 mM 
EDTA, 10% glycerol, 1mM DTT) for 15 min at RT. Visibility of proteasomal activity 
was achieved by incubation with 200 µM LLVY-AMC substrate and 5 mM ATP (in 
developing buffer, pre-heated on 37 °C) for 15-30 min at RT followed by excitation 
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using UV light. Images were recorded with a digital camera (Olympus) to visualise 
the two fluorescent bands of active 26S and 30S proteasome complexes.  
3.3.9.2  Plate reader assay (96 well) 
20 µg protein of the supernatant were incubated with 200 µM LLVY-AMC 
substrate and 5 mM ATP in incubation buffer (450 mM Tris pH 7.8 at 4 °C, 15 mM 
Mg-Acetate, 15 mM MgCl2, 90 mM KCl, 1 mM DTT) at 37 °C for 30 min. Prior 
fluorescence detection, 0-100 µM of free AMC-standard was added in the upper 
row of the 96 well plate. Non-specific proteasome activity was determined by 
addition of 50 nM epoxomicin (Epoxo). Values were normalised as percentage to 
mock cells. 
3.3.10 Immunofluorescence 
Cells were cultured on cover slips in 24-well culture plates (40.000 cells/well) and 
induced with 0.5 µM PonA for 16 h. To visualise surface staining of PM-PrP, cells 
were washed in PBS and fixed in 4 % paraformaldehyde (PFA) for 20 min. 4 % 
PFA was prepared by heating 80 ml PBS to 60-70 °C and addition of 4 g PFA 
while stirring on a hot plate in the fume hood. Volume was adjusted to 100 ml with 
PBS, PFA was cooled down at room temperature and pH was adjusted to 7.4. For 
intracellular staining, cells were then incubated with 0.1 % Triton-X-100 in PBS 
containing Hoechst dye (bis-benzimid, 10 µg /ml) for 10 min at room temperature. 
After blocking with 1 % BSA in PBS for 30 min, cells were incubated with primary 
antibodies (dilutions see table 2, 2.1.6) against PrP (3F4 antibody), giantin, protein 
disulfide isomerase (PDI), early endosomal antigen 1 (EEA1), and Hsc70 in PBS 
at 37 °C for 1h. Alexa-594- and Alexa-488-labelled secondary antibodies 
(Molecular Probes) were used. After washing and embedding procedures 
(DakoCytomation, Dako, #S3023), the cells were examined by Zeiss LSM 510 
scanning confocal microscope. 
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3.3.11 Immunoprecipitation 
100 ng protein of the cell lysates were incubated with a 1:500 dilution of the anti-
PrP antibodies 6H4, R340 or SAF32 overnight at 4 °C. Antibody-protein 
complexes were immobilised by adding 20 µl magnetic protein G-sepharose beads 
(Amersham Pharmacia, # 71-7083-00 AG) for 1 h at 4 °C. After several washing 
steps with 500 µl PBS, the beads-bound antibody-protein complexes were dried 
10 min in a spinvac (Eppendorf) and suspended in 1 x sample buffer without β-
mercaptoethanol. After boiling for 5 min at 95 °C the immunoprecipitation samples 
were loaded on a gel for SDS-PAGE followed by immunoblot analysis with 3F4 
anti-PrP antibody and anti-Hsc70 antibody (Table 2, 3.1.6). 
3.3.12 Cellular fractionation 
Mock-, Cy-PrP- or PM-PrP-transfected N2a cells were washed with PBS, 
harvested with 1 mM EDTA in PBS and centrifuged at 200 x g at 4 °C. Cells were 
lysed by shaking in bidestillated water (bidest) containing 1 mM DTT at 4 °C for 1 
h followed by centrifugation at 16.100 x g and 4 °C for 30 min. Supernatants 
served as soluble cytosolic fraction. Pellets were suspended in 50 µl NP40 
containing buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1 % NP40 and 1 mM DTT), 
incubated on ice for 15 min and centrifuged at 16.100 x g and 4 °C for 10 min. 
Supernatants comprised the insoluble membrane fraction.  
3.4 Statistics and fitting  
Standard abbreviation and significance level were calculated using Origin6.0. To 
test the significant difference of two samples (n > 6), populations was analysed 
with the t-test (two populations) using test type “independent” and a significance 
level of 0.05. Fitting of the kinetics of Cy-PrP and PM-PrP degradation were also 
done by Origin6.0.    
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4 Results 
It has been shown for the first time in 2002 that small quantities of a new PrP 
isoform, called Cy-PrP, produced by retro-translocation from the ER into the 
cytosol induces cytotoxicity in neuronal N2a cells (Ma et al., 2002b). In a 
transgenic mouse model Cy-PrP causes neuronal cell loss and gliosis in the 
granular layer of the cerebellum, which results in a phenotype characterised by 
ataxia, tail rigidity, frequent scratching and weight loss. These are typical 
symptoms associated with prion diseases. However, the mechanisms for neuronal 
cell death and the pathology caused by Cy-PrP are still unknown.  
In this study the Cy-PrP protein was expressed in neuronal N2a cells, which 
served as model cell line, using an inducible expression system. The inducible Cy-
PrP expression of Cy-PrP facilitates detailed characterisation of Cy-PrP-mediated 
cytotoxicity in a time dependent in this cell type. 
4.1 Generation and expression of Cy-PrP and PM-PrP 
4.1.1 Generation of Cy-PrP and PM-PrP 
N2a cells are murine neuroblastoma cells harbouring endogenous prion protein on 
their cell surface. Thus, transgene PrPs bearing an internal tag were cloned to 
distinguish them from the endogenous PrP. To avoid unspecific effects on protein 
conformation and function by common protein tags (Bian et al., 2006; Ledent et 
al., 1997; Supattapone et al., 2000), a cDNA encoding a chimeric mouse-hamster-
mouse PrP, MH2M (Scott et al., 1993), was used to generate Cy-PrP and PM-PrP 
(Fig. 5).  
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Fig. 5  Generation of chimeric Cy-PrP and PM-PrP. (A) Genomic DNA of transgenic MH2M 
mice encodes chimeric mouse-hamster-mouse PrP. The open reading frame (ORF) expresses 
MH2M-PrP protein (aa1-254) carrying the 3F4 anti-PrP antibody epitope (turquoise). cDNA of 
MH2M PrP from pPrPcDNAMH2M was used to generate Cy-PrP and PM-PrP. (B) PM-PrP and Cy-
PrP DNA-fragments were amplified from pPrPcDNAMH2M by PCR using specific forward and 
reverse primer pairs providing BamHI and EcoRI restriction sites for subsequent cloning into 
destination vectors. The N-terminal signal peptide (NSP, green) and the C-terminal GPI anchor 
sequence (yellow) were excluded to generate Cy-PrP fragment. 
The PM-PrP- and Cy-PrP-DNA-fragments were amplified from pPrPcDNAMH2M 
(M.G. Barenco, unpublished) by PCR using specific recombinant forward and 
reverse primer pairs with introduced BamHI and EcoRI restriction sites. These 
restriction sites were used for cloning into the destination vectors pIND and 
pcDNA3.1 to allow inducible and constitutive expression in eukaryotic cells. In 
addition to both PrP variants, the green fluorescence protein (GFP) was cloned 
into the pIND vector to test transfection efficiency and induction of gene 
expression after treatment with PonA. The generated constructs are listed in Table 
4.  
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Table 4   Generated plasmids encoding transgene PrP or GFP 
Name of construct  Transgene 
pIND-CyPrP MH2M  Cy-PrP 
pIND-PMPrP MH2M  PM-PrP 
pcDNA-CyPrP MH2M  Cy-PrP 
pcDNA-PMPrP MH2M  PM-PrP 
pIRES-puroCy-PrP MH2M  Cy-PrP 
pIND-GFP GFP 
 
4.1.2 Ecdysone-inducible expression system 
4.1.2.1  Functionality of the inducible expression system 
To test the inducible expression system, N2a cells were transiently co-transfected 
with plasmids encoding the GFP and the transactivator VgRXR followed by PonA 
treatment. Induced GFP expression was monitored by fluorescence microscopy 
and quantified by FACS analysis (Fig. 6). Strong GFP expression was obtained 
after 1 µM PonA treatment for 16 h, whereas non-treated cells showed almost no 
GFP expression (Fig. 6A).  
 
 
Fig. 6  Proof of principle: ecdysone-inducible gene expression in N2a cells. N2a cells were 
transiently co-transfected with transactivator VgRXR-encoding and GFP-encoding target plasmid. 
GFP expression was induced by adding PonA (1µM) for 16 h. (A) Immunofluorescence microscopy 
of GFP expression in presence or absence of PonA. (B) FACS analysis of GFP fluorescence after 
PonA treatment.  
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Relative quantification of GFP expression by FACS analysis showed 60-70 % 
transfection efficiency in PonA treated N2a cells (Fig. 6B), which was confirmed in 
at least three independent experiments. Increasing PonA concentrations from 0.5 
to 2 µM only weakly increased the GFP expression levels, whereby the GFP 
transfection efficiency was not affected (data not shown). These data 
demonstrated functionality of the ecdysone-inducible expression system in both 
N2a. The latter was confirmed in another cell line 293T (data not shown).  
4.1.2.2  Inducible expression of Cy-PrP and PM-PrP 
Inducible expression of Cy-PrP and PM-PrP were tested in neuronal N2a cells and 
non-neuronal 293T cells in transient transfection experiments. After transfection, 
cells were cultivated in presence or absence of 1 µM PonA for 16 h followed by 
preparation of cell extracts and the detection of Cy-PrP and PM-PrP by 
immunoblotting using the 3F4 antibody (Fig. 7). 
 
 
 
 
Fig. 7  Cy-PrP and PM-PrP transiently expressed in N2a and 293T cells after induction with 
PonA. Detection of Cy-PrP and PM-PrP in presence or absence of PonA (1µM) for 16 h using 3F4 
antibody in immunoblot analysis. 3F4 antibody recognises only the transgenic 3F4-tagged PrP and 
not the endogenous murine PrP. The arrow indicates the single band of Cy-PrP around 27 kDa. 
The expression of both, Cy-PrP and PM-PrP, was detectable in N2a and 293T 
cells (Fig. 7) upon PonA treatment. The PM-PrP protein (Fig. 7, right panel) 
showed the characteristic three band pattern caused by the different 
glycosylations, whereas Cy-PrP (Fig. 7, left panel) appeared as single band of 
38 Results 
around 27 kDa due to missing glycosylations. This was confirmed by PNGaseF 
treatment, which did not alter the migration of the single band (data not shown). In 
contrast, untreated cells showed no expression of Cy-PrP and PM-PrP, 
respectively.  
These data showed the induced expression of Cy-PrP and PM-PrP by the 
ecdysone-inducible expression system in N2a and 293T cells, which was used in 
all following transient transfection experiments.  
As observed for GFP expression, increasing PonA concentration from 0.5 to 2 µM 
showed no significant effect on Cy-PrP and PM-PrP expression levels in N2a cells, 
(data not shown). In the following experiments only 0.5 µM PonA were used to 
analyse Cy-PrP and PM-PrP proteolysis and cellular distribution.  
4.2 Analysis of cytotoxicity in Cy-PrP expressing cells 
4.2.1 Cell viability in Cy-PrP expressing N2a cells 
Small amounts of Cy-PrP should be extremely toxic to neuronal cells after 24 h of 
Cy-PrP expression (Ma et al., 2002b). To examine this postulated cytotoxic 
potential of Cy-PrP in a neuronal cell line, viability assays were performed 24 h 
and 48 h after Cy-PrP induction in N2a cells (Fig. 8A and B). Cy-PrP expression 
was induced by treatment with 2 µM of PonA to ensure that the inducer was given 
in excess for maximal transgene expression. Two methods based on different 
mechanisms were applied to detect Cy-PrP-specific effects on cell viability 
compared to cells expressing PM-PrP or to cells transfected with the empty vector 
(mock). The relative values were normalised to mock cells. Functionality of the 
assays is demonstrated by the Triton-X-100 sample. Data for relative cell viabilities 
determined by measurement of mitochondrial respiratory activity (MTT assay) are 
shown in Fig. 8A.  
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Fig. 8  Viability and cytotoxicity in neuronal N2a cells after Cy-PrP and PM-PrP expression. 
Cells were transiently transfected with Cy-PrP or PM-PrP and their expression was induced with 2 
µM PonA. Cell viability and cytotoxicity were measured by MTT assay (A) and LDH assay (B) 24 h 
or 48 h post-induction. Cells treated with 9 % triton served as positive control. The values (A-B) are 
shown as % of mock control (mean ± SEM). Asterisks indicate values significantly different from 
mock controls (P* ≤ 0.05). Two asterisks matter significance different to mock (P* < 0.05) but not to 
non-induced samples. The bars represent at least three independent experiments.  
Cell viability of N2a cells was not affected by 24 h Cy-PrP expression (column + 
PonA) as compared to cells devoid of Cy-PrP (Column - PonA). No differences in 
cell viability were observed in comparison with PM-PrP-transfected (column 5) and 
PM-PrP-expressing cells (column 6) or with mock cells. After longer expression 
period (48h), cell viability is reduced around less than 20 % in N2a cells 
expressing Cy-PrP (right panel, column 4) as compared to mock cells. The 
detected reduction of cell viability was not significantly different to transfected cells 
devoid of Cy-PrP protein (right panel, column 3). PM-PrP transfection and 48 h 
expression did not effect the cellular survival (right panel, column 6). Triton-X-100 
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treated cells showed approximately 60-70 % reduction of cell viability at both time 
points (*P < 0.05). Furthermore, cytotoxicity of Cy-PrP and PM-PrP expression in 
N2a cells were determined by measurement of cytosolic LDH release due to the 
loss of membrane integrity (LDH assay, Fig. 8B). Triton-X-100 treatment 
demonstrated cytotoxic effects (*P < 0.05) after 24 h and 48 h. In contrast, neither 
cells expressing Cy-PrP (column 4) nor PM-PrP-expressing cells (column 6) 
answered with detectable releases of LDH. All transfected samples did not show 
increased cytotoxicity after 24 h and 48 h. Viability assays were not performed at 
longer time points due to decreasing Cy-PrP amounts observed 72 h post-
transfection (data not shown). Indeed, the viability of Cy-PrP expressing cells was 
comparable to that observed for the PM-PrP expressing and mock transfected 
cells.  
 
Fig. 9  PonA induced gene expression in samples used for cell survival assays. (A) PonA 
induced GFP expression after 24 h in the samples used for MTT and LDH assay. (B) One 
representative immunoblot of Cy-PrP and PM-PrP expression in the samples used for MTT and 
LDH assay at 24 h post-induction. 
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To monitor for transfection efficiency and PonA-mediated induction of gene 
expression, the GFP encoding plasmid was simultaneously transfected followed 
by visualisation of GFP expression by fluorescence microscope imaging (Fig. 9A). 
GFP was highly expressed 24 h post-induction with PonA, while most of the 
untreated cells did not express GFP. The weak background of GFP due to leakage 
of the inducible system in transiently transfected cells was negligible. The 
induction of Cy-PrP and PM-PrP expression in the cells used in both assays was 
monitored by immunoblot analysis using the 3F4- antibody (Fig. 9B). Cy-PrP and 
PM-PrP induction was clearly detected in the samples incubated with 2 µM PonA.  
4.2.2 Cell viability in Cy-PrP expressing 293T cells 
It was postulated that Cy-PrP might be toxic in a cell type dependent manner (Ma 
et al., 2002b). In N2a cells, which express endogenous PrP
C, no Cy-PrP-mediated 
cytotoxicity was measured (Fig. 8, see 4.2.1). If endogenous PrP
C has an 
influence on toxicity of Cy-PrP, a cytotoxic effect should be measured in cells 
lacking endogenous PrP
C. To address this question, cell survival of 293T cells 
expressing Cy-PrP and PM-PrP was tested using the MTT assay (Fig. 10). 
   
 
Fig.  10 Viability after Cy-PrP and PM-PrP expression in 293T cells. Cells were transiently 
transfected with Cy-PrP or PM-PrP and their expression was induced with 2 µM PonA. Cell viability 
was measured by MTT assay 24 h post-induction. The viability values are shown as % of mock 
control (mean ± SEM). The bars represent three independent experiments.  
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These are non-neuronal cells, which do express very low levels of endogenous 
PrP
C (LeBlanc et al., 2004). Transgene PrPs were similar expressed in both, N2a 
cells and 293T cells, after induction for 24 h with 2 µM PonA (data not shown). 
Both Cy-PrP and PM-PrP expression did not affect cell viability of 293T cells (Fig. 
10).  
Taken together, Cy-PrP was neither toxic to neuronal N2a nor to non-neuronal 
293T cells at the indicated time points. Hence, Cy-PrP toxicity seems to be not 
directly related to the endogenous PrP
C level or the cell type in these in vitro 
models. 
4.2.3 Caspase-3 activity in Cy-PrP expressing N2a cells 
In the previously published work (Ma et al. 2002b), Cy-PrP toxicity in N2a cells 
was analysed by a terminal-dUTP nick end labelling (TUNEL) assay, a method for 
determination of apoptosis. Within 24 h of Cy-PrP expression TUNEL positive cells 
increased from 6 to 14 %. This is not as high as expected for an extremely toxic 
protein. Establishment of the TUNEL-assay (fluorescent and colorimetric) for the 
N2a cell model used in this study failed due to lack of reproducibility. Thus, 
another apoptosis marker was chosen to detect cytotoxicity in N2a cells after 24 h 
of Cy-PrP expression. Since several apoptosis inducing pathways involve 
caspase-3 activation, a specific enzyme caspase-3 activity test was established 
and used to analyse apoptosis triggered by Cy-PrP or PM-PrP after 24 h 
expression (Fig. 11). Caspase-3 activity was analysed in cell lysates incubated 
with the AMC-conjugated caspase-3 specific substrate DMQD. Free cleaved AMC 
was detected by fluorescence measurement. Relative caspase-3 activity in Cy-PrP 
and PM-PrP expressing N2a cells was calculated from the fluorescence units and 
normalised to PonA-treated mock cells (Fig. 11). No specific increase of caspase-
3 activity was detected in PonA-treated Cy-PrP expressing cells (column 4) as 
compared to non-treated (column 3) and mock cells (column 1 and 2) after 24 h. 
Similarly, PM-PrP expression (column 6) did not specifically affect caspase-3 
activity in N2a cells.  
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Fig. 11 Caspase-3 activity in neuronal N2a cells after Cy-PrP and PM-PrP expression. Cells 
were transiently transfected with Cy-PrP or PM-PrP and their expression was induced with 2 µM 
PonA. Caspase-3 activity detected by fluorescence measurement of the cleaved AMC from the 
substrate peptide DMQD-AMC. The values are shown as % of mock control (mean ± SEM). The 
data represent three independent experiments.  
4.3 Proteolysis of Cy-PrP and PM-PrP in N2a cells  
4.3.1 Kinetics of Cy-PrP and PM-PrP proteolysis 
It has been shown that proteasome inhibition causes accumulation of Cy-PrP and 
that such Cy-PrP is detergent-insoluble and partially PK-resistant (Ma and 
Lindquist, 2002). Moreover, Cy-PrP appears to have the ability to promote further 
conversion of additional PrP to the same state. All these properties are also 
characteristic for PrP
Sc
, the TSE-infectious agent (Kocisko et al., 1994; Prusiner, 
1998). In order to see whether transiently expressed Cy-PrP has similar 
characteristics like PrP
Sc when the proteasomal system is functional, cell extracts 
of N2a cells containing transiently expressed Cy-PrP (Fig. 12, 0 µg/ml) were 
digested with 1 or 10 µg/ml PK (Fig. 12, Cy-PrP 1 and 10 µg/ml) and analysed by 
immunoblotting using 3F4 antibody. As a control served cell extracts from N2a 
cells harbouring PrP
Sc (N2a58/22L). 
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Fig. 12  PK-digestion of Cy-PrP expressed in N2a cells. Cells were transiently transfected with Cy-
PrP and their expression was induced overnight with 0.5 µM PonA. Detection of PK-resistant Cy-
PrP analysed by immunoblot using 3F4 antibody following proteinase K digestion. Mock 
transfected cells served as negative and scrapie-infected N2a58/22L as positive control. PrP
res 
presents the PK-resistant part of PrP
Sc after PK digestion including the N-terminal truncation of 90 
aa.  
No PK-resistant Cy-PrP was detected after digestion with 1 or 10 µg/ml PK. In 
PrP
Sc-containing N2a-58/22L cells significant amounts of PK-resistant PrP (PrP
res) 
were detected (Fig. 12, last lane) following digestion with double concentrated PK 
(20 µg/ml). Cy-PrP was completely degraded by PK and does not accumulate in 
PK-resistant aggregates. PK is a fungal protease with broad substrate spectrum. 
To analyse the stability of Cy-PrP as compared to PM-PrP in N2a cells containing 
mammalian proteases, the kinetics of Cy-PrP and PM-PrP degradation were 
determined by detection of Cy-PrP and PM-PrP at different time points by 
immunoblotting (Fig. 13). The stability of Cy-PrP in comparison to PM-PrP was 
reflected by the calculated half life of both PrPs in N2a cells. Amounts of PM-PrP 
and Cy-PrP decreased within 6-12 h after PonA withdrawal. Detection of β-actin 
demonstrated equal protein loading. The densitometric quantification showed that 
the half life for both PM-PrP and Cy-PrP was between 7 and 8 h (Fig. 13B). While 
PrP
C is synthesised and degraded relatively rapidly (t0.5 ~ 5 h), PrP
Sc is 
synthesised slowly and appears to accumulate (t0.5 ~ 15 h) (Borchelt et al., 1990). 
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Cy-PrP degradation was not prolonged as compared to PM-PrP indicating 
absence of PrP
Sc-like stability and protease resistance.  
 
 
Fig. 13  Degradation of Cy-PrP and PM-PrP in N2a cells. Cells were transiently transfected with 
Cy-PrP or PM-PrP and their expression was induced overnight with 0.5 µM PonA. PonA-containing 
medium was replaced with normal DMEM for indicated time points. (A) Time-dependent decrease 
of PM-PrP (left) and Cy-PrP (right) analysed by immunoblot using 3F4 antibody. Immunoblot 
against actin served as positive control. (B) Degradation curve for PM-PrP and Cy-PrP determined 
by densitometric evaluation of four different immunoblot experiments. The values are normalised 
as percentage to the PrP signal at time point 0h (mean ± SEM). Curve fitting was achieved by 
interpolation using the Boltzmann model with indicated chi-square values. Fitting function was used 
to calculate half life (t0.5) of Cy-PrP and PM-PrP.  
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4.3.2 Role of proteasome in Cy-PrP and PM-PrP proteolysis 
4.3.2.1  Proteolysis under proteasome inhibition 
Since mutant PrP or retro-translocated wt-PrP accumulates in cells with impaired 
proteasome activity (Fioriti et al., 2005; Ma et al., 2001; Ma et al., 2002a; Wang et 
al., 2005), it was assumed that Cy-PrP might be degraded by the proteasome. 
Thus, degradation of PM-PrP and Cy-PrP was monitored in N2a cells between 0 
and 12 h upon removal of PonA treatment in absence or presence of the specific 
proteasome inhibitor epoxomicin (Fig. 14).  
 
 
Fig. 14 PM-PrP and Cy-PrP proteolysis under proteasome inhibition. Cells were transiently 
transfected with PM-PrP or Cy-PrP and their expression was induced overnight with 0.5 µM PonA. 
PonA-containing medium was replaced with either DMEM or supplemented with the proteasome 
inhibitor epoxomicin (Epoxo) for indicated time points. (A) PM-PrP and Cy-PrP degradation 
analysed by immunoblot using 3F4 antibody. Immunoblot against actin served as positive control. 
(B) Densitometric evaluation of the PM-PrP and Cy-PrP signal for four different immunoblot 
experiments normalised to the PrP signal at time point 0 h.  
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The amount of PM-PrP or Cy-PrP was analysed by immunoblots at indicated time 
points. The PM-PrP showed independently from the proteasome inhibition 
decreasing signal intensities (Fig. 14A, left panel). Densitometric quantification 
revealed that mature PM-PrP was proteasome-independently degraded with no 
altered half life (Fig. 14B, left panel). This was expected, since PM-PrP is located 
on the cell surface or in cellular compartments such as recycling vesicles and the 
Golgi apparatus where the proteasome is not located. However, long term 
exposure of immunoblot seen in Fig. 13 showed accumulation of the non-
glycosylated PrP form after epoxomicin treatment (Fig. 15, + Epoxo 4-12 h) as 
compared to untreated cells (Fig. 15, - Epoxo 4-12 h) indicating retro-translocation 
of PrP from the ER into the cytosol for further degradation by the proteasome 
(Fioriti et al., 2005; Wang et al., 2005).  
 
 
Fig. 15 Accumulation of non-glycosylated band of PM-PrP after proteasome inhibition. Cells 
were transiently transfected with PM-PrP or Cy-PrP and their expression was induced overnight 
with 0.5 µM PonA. PonA-containing medium was replaced with either DMEM or supplemented with 
the proteasome inhibitor epoxomicin (Epoxo) for indicated time points. Panel shows PM-PrP 
signals analysed by immunoblot using 3F4 antibody following over exposure. Arrow indicates the 
non-glycosylated band of PM-PrP. 
In the case of Cy-PrP a constant immunoblot signal was detected between 8 and 
12 h in presence of epoxomicin (Fig. 14A, right panel), whereas untreated cells 
showed a continuous decrease of the Cy-PrP signal. These data demonstrate a 
strong inhibition of Cy-PrP proteolysis in presence of epoxomicin. Densitometric 
quantification of four independent experiments clearly confirmed that Cy-PrP 
proteolysis was dramatically decelerated by proteasome inhibition (Fig. 14B, right 
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panel). The half life of Cy-PrP was increased to more than 12 h (see black column) 
by proteasome inhibition.  
Additionally, the Cy-PrP content was examined after 16 h PonA treatment in the 
presence of different proteasome inhibitor concentrations to support the data that 
Cy-PrP is a proteasomal substrate (Fig. 16). Immunoblot analysis demonstrated 
that Cy-PrP clearly accumulated with increasing epoxomicin concentration (Fig. 
16A). Densitometric quantification confirmed that increasing proteasomal inhibition 
resulted in an approximately 4-fold increase of Cy-PrP content in N2a cells (Fig. 
16B).  
 
 
 
Fig. 16  Cy-PrP accumulation after proteasome inhibition in N2a cells. Cells were transiently 
transfected with Cy-PrP and expression was induced with 2 µM PonA for 24 h. 16 h prior to cell 
lysis 50 nM epoxomicin (Epoxo) was added. (A) Cy-PrP accumulation analysed by immunoblot 
using 3F4 antibody. Immunoblot against actin served as positive control. (B) Densitometric 
evaluation of Cy-PrP signals from four different immunoblot experiments normalised to the Cy-PrP 
signals without Epoxo treatment (mean ± SEM).Value of 50 nM Epoxo treated cells was 
significantly different to untreated Cy-PrP cells (P* < 0.05). 
The correlation of Cy-PrP accumulation with increasing proteasome inhibitor 
concentration confirmed the results observed in Cy-PrP proteolysis experiments 
indicating that Cy-PrP is a substrate of the proteasome and must be therefore 
present in the cytosol.  
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4.3.2.2  Proteasome activity after Cy-PrP expression  
Since Cy-PrP is degraded by the proteasome, overexpression of Cy-PrP as well 
as PM-PrP could influence basic proteasomal activity in transiently transfected 
N2a cells. Thus, the activity of the 26S ATP-dependent proteasome complex was 
determined for Cy-PrP and PM-PrP expressing N2a cells using a native enzymatic 
activity gel (Fig. 17A). The cleavage of the proteasomal substrate LLVY-AMC by 
native 26S proteasome molecules in the gel was visible through fluorescence.  
 
 
 
Fig. 17 Proteasome activity and content in N2a cells expressing Cy-PrP or PM-PrP. Cy-PrP 
or PM-PrP expression was induced in transiently transfected N2a cells by adding 0.5 µM PonA for 
16 h. Proteasomal cleavage of suc-LLVY-AMC was measured as fluorescence at 380 nm 
excitation and at 460 nm emission (A and C). (A) ATP-dependent proteasome activity observed as 
blue fluorescent bands in a native gel. (B) Immunoblot of 20S proteasome using anti-20S α-subunit 
antibody. Anti-GAPDH served as loading control. (C) Plate reader assay of 26S proteasome 
activity. Proteasome activity is normalised to mock cells (mean ± SEM). The value represents three 
independent experiments.  
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Strong substrate turnover was observed for cells expressing Cy-PrP and PM-PrP 
(Fig. 17A, lane Cy- and PM-PrP, + PonA). However, mock-transfected N2a cells 
showed also increased cleavage of the proteasome substrate (lane mock +) 
indicating that the transfection procedure alone elevates proteasome activity.  
To exclude altered 26S proteasome activity in transfected cells due to increased 
proteasome expression, the samples were examined for their proteasome content 
by immunoblotting using a specific anti-20S α-subunit antibody (Fig. 17B). 
Proteasomal α-subunit protein levels were equal in non-transfected (N2a, -PonA) 
and transfected cells (mock, Cy- and PM-PrP, + PonA) independent of transgene 
expression demonstrating that increased proteasome activity was not the result of 
increased proteasome levels per se. Native proteasome activity gels allow 
qualitative analysis of the cellular proteasome activity. Since all of the transfected 
cells answered with a clear increase of the 26S proteasome activity, a second 
more quantitative plate reader fluorescence assay was applied to support the 
qualitative native gel results. In the plate reader assay the cleavage of the 
proteasomal substrate LLVY was detected by digital measurement of the emitted 
fluorescence units. Calculated proteasome activity values were normalised to the 
PonA-treated mock cells (Fig. 17C). Neither Cy-PrP (column Cy-PrP, + PonA) nor 
PM-PrP overexpression (column PM-PrP, + PonA) in N2a cells affected the 
proteolytical activity of the proteasome system as compared to the mock 
transfected N2a cells (column mock, + PonA). PonA itself exhibited no influence 
on 26S proteasome activity as demonstrated by columns - and + PonA of mock 
cells. Proteasome activity assays revealed transfection-mediated proteasome 
activation. The potential Cy-PrP-mediated cytotoxicity could have been 
counterbalanced through unspecific increased proteasome-mediated proteolysis of 
Cy-PrP. 
4.3.3  Viability in Cy-PrP expressing N2a cells after proteasome 
inhibition 
One reason for the lack of Cy-PrP cytotoxicity in transiently transfected N2a cells 
might be the increased proteasome activity caused by the transfection procedure, 
because Cy-PrP might be faster degraded by the proteasome. However, it was 
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proposed that neuronal death could be triggered by accumulation of cytosolic PrP 
due to impairment of the proteasomal degradation system. Thus, reduction of the 
proteasome activity by specific inhibitors might reveal cytotoxicity caused by Cy-
PrP overexpression in N2a cells. To test this hypothesis, Cy-PrP and PM-PrP 
expression was induced in N2a cells in presence of the proteasome inhibitor 
epoxomicin followed by MTT viability assays 24 h post-induction (Fig. 18A). 
 
 
Fig. 18  Proteasome inhibition does not reveal Cy-PrP-mediated cytotoxicity in N2a cells. 
Cells were transiently transfected with PM-PrP or Cy-PrP and their expression was induced with 2 
µM PonA for 24 h. 16 h prior to viability measurement 50 nM epoxomicin (Epoxo) was added. (A) 
Cell viability was measured by MTT assay 24 h post-induction. The values are shown as % of 
mock control (mean ± SEM). Cells treated with 9 % triton served as positive control, which was 
significantly different from mock control (P ≤ 0.05). (B) Proteasome inhibition in N2a cells treated 
with 50 nM epoxo detected by measuring 26S-proteasome-mediated LLVY-AMC cleavage in plate 
reader. Proteasome activity was normalised to untreated N2a cells (mean ± SEM). The value 
represents three independent experiments and was significantly different to untreated N2a cells (*P 
< 0.05). (C) One representative immunoblot of Cy-PrP and PM-PrP expression in the samples 
used for MTT and LDH assay at 24 h post-induction. 
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Neither Cy-PrP (column Cy-PrP, + PonA) nor PM-PrP (column PM-PrP, + PonA) 
overexpressed in N2a cells during impaired proteasome activity influenced the 
cellular survival as compared to the non-induced (column Cy- and PM-PrP, - 
PonA) and mock-transfected N2a cells (column mock, + PonA). In contrast, 
treatment with 9% Triton-X-100 showed significantly (P* < 0.05) decreased 
survival of N2a cells (around 50 % to mock, last column). No toxic potential 
induced by PM-PrP was detected. To confirm the effective inhibition of the 
proteasome, 26S proteasome activity was analysed in fluorescence substrate-
cleavage assays (Fig. 18B). Treatment with 50 nM of epoxomicin was sufficient to 
inactivate the proteasomal 26S activity in N2a cells. Immunoblot using 3F4 
antibody ensured Cy-PrP and PM-PrP expression (Fig. 18C) in the samples used 
for MTT assays shown in Fig. 18A. 
These results suggest that N2a cells tolerate high Cy-PrP levels and cytotoxicity of 
Cy-PrP is controlled by other cellular mechanisms than degradation through the 
proteasome complex.  
4.4  Cellular localisation of Cy-PrP and PM-PrP in N2a 
cells 
4.4.1 Intracellular localisation of Cy-PrP  
The lack of Cy-PrP glycosylation and the proteasome-mediated proteolysis of Cy-
PrP indicate cytosolic localisation of Cy-PrP. To confirm this cellular localisation, 
subcellular fractions were tested for the presence of Cy-PrP expression by 
immunoblotting (Fig. 19). Following PonA induction, N2a cells expressing Cy-PrP 
or PM-PrP were subjected to hypoosmotic lysis followed by centrifugation to 
separate the low density fraction containing cytosolic proteins and small vesicles 
from the high density fraction containing plasma membrane and large cellular 
compartments. Both fractions were analysed by immunoblot. As expected, almost 
no PM-PrP was detectable in the cytosolic fraction (Fig. 19, left panel, lane Pm-
PrP + PonA) whereas a strong PM-PrP signal was found in the membrane fraction 
(Fig. 19, right panel, lane PM-PrP, + PonA). In contrast, Cy-PrP was localised in 
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both the cytosolic fraction (Fig. 19, left panel, laneCy-PrP, + PonA) and the 
membrane fraction (Fig. 19, right panel, lane Cy-PrP, + PonA). In the latter only a 
low Cy-PrP concentration was detected, the majority of Cy-PrP was located in the 
cytosol. Counterstaining of β-actin, known as cytosolic marker, and calnexin, 
known as ER-membrane marker, underscored separation of both fractions, 
although weak signals of each marker was found in unrelated fractions indicating 
minor contaminations. 
 
 
 
Fig. 19 Cy-PrP mainly localises in the low density-cytosol fraction of N2a cells. Cy-PrP or 
PM-PrP expression was induced in transiently transfected N2a cells by adding 0.5 µM PonA for 16 
h. Cells were lysed and subcellular fractions of low density (cytosol) and high density (membranes) 
were analysed for Cy-PrP and PM-PrP expression by immunoblotting using 3F4 antibody. Anti-β-
actin and anti-calnexin served as controls for both fractions.  
However, these data confirmed the assumption that Cy-PrP is mainly localised in 
the cytosolic compartment whereas PM-PrP was localised in membranes, which 
was in line with the results showing that overexpressed full length PrP is found at 
the cell surface and in the Golgi apparatus (Haraguchi et al., 1989; Stahl et al., 
1987; Taraboulos et al., 1992).  
To strengthen these observations, extracellular and intracellular 
immunofluorescence analyses were performed to visualise microscopically the 
localisation of overexpressed Cy-PrP and PM-PrP in N2a cells (Fig. 20). In 
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extracellular staining, a strong membrane staining was observed for PM-PrP (red) 
on the cell surface (Fig. 20A bottom panel). Extreme slight signals were also found 
for Cy-PrP (Fig. 20A middle panel), which showed a dot-like pattern (speckles) 
differently to PM-PrP.  
 
 
Fig.  20  Cy-PrP accumulates in fine foci throughout N2a cells and is partially nucleus-
associated. Cy-PrP or PM-PrP expression was induced in transiently transfected N2a cells by 
adding 0.5 µM PonA overnight. Immunofluorescence staining was performed using the anti-PrP 
3F4 antibody (A and B) and anti-giantin antibody (B) followed by fluorescent dye conjugated 
secondary antibodies. (A) Extracellular staining with 3F4 anti-PrP without cell permeabilisation to 
detect PM-PrP and Cy-PrP (both red) (B) Extra- and intracellular PrP staining of permeabilised 
cells. Yellow colour in the merged images provides co-localisation of PM-PrP with giantin (green). 
Nucleus staining was performed with bis-benzimid (Hoechst 33342) solution (blue). scale bar: 20 
µm 
Intracellular staining uncovered that Cy-PrPs (red) formed indeed those 
intracellular speckles unusual for cytosolic proteins (Fig. 20B, middle panel) and 
suggested that some cells in the extracellular staining were slightly permeable 
after fixation. In contrast, intracellular staining of PM-PrP confirmed its membrane-
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distribution but showed also a structured pattern close to the nuclei (Fig. 20B, 
bottom panel). To discriminate intracellular localisation of Cy-PrP and PM-PrP, 
cells were counterstained for giantin, which is a known marker for the Golgi 
apparatus (Fig. 20B). Indeed, intracellular PM-PrP co-localised with giantin (Fig. 
20B, bottom panel, merged) suggesting that PM-PrP was associated with the 
Golgi apparatus. In contrast, Cy-PrP did not co-localise with giantin and the dot-
like structures of intracellular Cy-PrP were distinct from the PM-PrP pattern. Thus, 
Cy-PrP was not associated with the Golgi apparatus (Fig. 20B, middle panel, 
merged). However, a minority of intracellular Cy-PrP exhibited more diffuse 
staining pattern (Fig. 20B, middle panel, arrows). Counterstaining of intranuclear 
chromatin by bis-benzimid (Hoechst 33342) revealed that those Cy-PrP molecules 
localised with the nuclei. To analyse more detailed the intranuclear localisation of 
Cy-PrP, N2a cells were co-stained with bis-benzimid (Hoechst 33342) and Cy-
PrP-antibody, and multilayer images were recorded. Focusing through several z-
layers of different cells revealed that Cy-PrP was not located in the nucleus and 
the diffuse distribution rather surrounded the nucleus (Fig. 21). Thus, Cy-PrP 
might have been associated with other subcellular structures or compartments.  
 
 
 
Fig. 21  Immunofluorescence of nucleus-associated Cy-PrP in N2a cells. Cy-PrP expression 
was induced in transiently transfected N2a cells by adding 0.5 µM PonA overnight. Intracellular 
immunofluorescence staining was performed in Triton-permeabilised cells using the anti-PrP 3F4 
antibody for Cy-PrP detection and bis-benzimid (Hoechst 33342) solution for nucleus staining 
(blue). Images were obtained by stack recording using Zeiss LSM 510 scanning confocal 
microscope. Images of different z-layers (µm) are shown. Scale bar: 20 µm 
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4.4.2 Cy-PrP co-localisation with Hsc70 in EEA1 positive vesicles 
The above presented results demonstrated that overexpressed Cy-PrP formed 
fine foci throughout the N2a cells, different to a diffuse and homogenous 
distribution often observed for cytosolic proteins, and Cy-PrP might be associated 
with other compartments such as ER or endosomes and lysosomes. Thus, 
intracellular staining of Cy-PrPs was repeated along with different known markers 
characteristic for those compartments. Co-staining of Cy-PrP with disulfide 
isomerase (PDI), a marker for the ER, did not show co-localisation in merged 
images (Fig. 22, first panel) indicating Cy-PrP was not translocated into the ER 
lumen. In contrast, co-staining of Cy-PrP along with early endosome antigen 1 
(EEA1), a marker for the presented endosomal compartment revealed intense 
overlap of both patterns in merged pictures (Fig. 22, middle panel) strongly 
suggesting that overexpressed Cy-PrP is recruited to endocytic vesicles. 
Recruitment of overexpressed cytosolic proteins to endosomal/lysosomal vesicles 
has been described and chaperones, especially Hsc70/Hsp70 and their co-
chaperones, are involved in this process (Agarraberes and Dice, 2001; Chiang et 
al., 1989; Cuervo et al., 1997). Thus, Cy-PrP overexpressed in N2a cells was 
stained together with Hsc70 (Fig. 22, bottom panel). Indeed, the specific Hsc70 
staining provided an inhomogeneous intracellular localisation similar to the 
speckles observed for Cy-PrP. Merging the pictures revealed intense overlap of 
both, Cy-PrP and Hsc70 staining, indicating that Cy-PrP and Hsc70 co-localise in 
N2a cells (Fig. 22, bottom panel, merged). 
To demonstrate that Hsc70 co-localised specifically with Cy-PrP, a second 
immunofluorescence experiment was performed including PM-PrP- and mock-
transfected N2a cells (Fig. 23). Neither in mock nor in PM-PrP-expressing cells 
Hsc70 clustered in dot-like structures (Fig. 23, top and bottom panel). In contrast, 
Cy-PrP expression has a striking effect on Hsc70 distribution showing 
homogenous Hsc70 was concentrated in fine foci (Fig. 23, middle panel), which 
co-localised with Cy-PrP speckles (Fig. 23, middle panel, merged).  
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Fig. 22  Cy-PrP co-localises with Hsc70 in EEA1-positive endocytic vesicles. Cy-PrP 
expression was induced in transiently transfected N2a cells by adding 0.5 µM PonA overnight. 
Cells were fixed, permeabilised with Triton-X-100, and stained with 3F4 anti-PrP antibody and anti-
PDI, anti-giantin, anti-EEA1 or anti-Hsc70 antibody followed by Alexa488 (green)-conjugated and 
Alexa594 (red)-conjugated secondary antibody. Nucleus staining was performed with bis-benzimid 
(Hoechst) solution (blue). Co-staining of Cy-PrP (red) with PDI, giantin, EEA1 or Hsc70 (green). In 
the merged images Cy-PrP co-localises with EEA1 or Hsc70, producing a yellow colour, which was 
not observed with compartment markers PDI and giantin. Scale bar: 20 µm  
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Fig. 23  Redistribution of cytosolic Hsc70 by Cy-PrP expression in N2a cells. Cy-PrP or PM-
PrP expression was induced in transiently transfected N2a cells by adding 0.5 µM PonA overnight. 
Cells were fixed, permeabilised with Triton-X-100, and stained with mouse anti-PrP antibody 3F4 
and rat anti-Hsc70 antibody followed by Alexa488 (green)-conjugated anti-rat and Alexa594 (red)-
conjugated anti-mouse secondary antibody. Nucleus staining was performed with bis-benzimid 
(Hoechst) solution (blue). Yellow colour in merged images provides co-localisation of Cy-PrP and 
Hsc70. Scale bar: 20 µm 
To test whether the intense dot-like Hsc70 staining in Cy-PrP expressing N2a cells 
was due to an increased Hsc70 protein level, cell extracts derived from mock, Cy-
PrP and PM-PrP expressing cells were analysed by immunoblot using a specific 
anti-Hsc70 antibody (Fig. 24). In addition, transgene expression was confirmed 
using 3F4 antibody. In all cell extracts Hsc70 was detectable in similar quantities 
(band around 70 kDa), which excluded that Hsc70 redistribution or accumulation in 
fine foci was caused by an increased Hsc70 protein level in the cytosol of Cy-PrP 
expressing N2a cells. 
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Fig. 24  Hsc70 level is not altered by Cy-PrP expression in N2a cells. Cy-PrP or PM-PrP 
expression was induced in transiently transfected N2a cells by adding 0.5 µM PonA for 16 h. Cells 
were harvested and lysates were analysed for Hsc70 expression by immunoblotting using anti-
Hsc70 antibody. Cy-PrP and PM-PrP expression was ensured using the 3F4 antibody. Right panel 
shows the coomassie stained gel as protein loading control. 
Summary, these results suggest that homogenous distributed Hsc70 directed 
accumulated Cy-PrP to fine foci structures by binding and trafficking of Cy-PrP to 
endosomal vesicles. This would explain why transiently overexpressed Cy-PrP 
was not toxic during inhibition of the proteasome system in N2a cells. 
4.4.3 Binding of Cy-PrP by Hsc70 
Immunofluorescence analyses provided the interesting result that Cy-PrP and 
Hsc70 co-localise in N2a cells, but did not proof direct binding of Cy-PrP by 
Hsc70. Therefore, specific Cy-PrP immunoprecipitation using the 3F4 antibody 
followed by immunoblot analysis with anti-Hsc70 may provide more detailed 
information on Cy-PrP/Hsc70 interaction. Unfortunately, the 3F4 antibody was not 
able to precipitate sufficient amounts of Cy-PrP from cell extracts as already 
observed by Wang et al. (2005). However, Cy-PrP was successfully 
immunoprecipitated using the anti-PrP antibodies 6H4, SAF32 and R340, which 
bind to different regions in the PrP sequence (Fig. 25A, lanes IP). Cy-PrP 
expression in the cell extracts of Cy-PrP transfected and induced N2a cells was 
also proven (Fig. 25A, lane L). Analysis of the supernatants of immunoprecipitation 
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experiments exhibited no signal for retained soluble Cy-PrP (Fig. 25A, lane S). 
Disadvantage of the used antibodies is their recognition of both transgene PrPs 
and endogenous murine PrP (PrP
C) in transfected N2a cells resulting in co-
precipitation of PrP
C and MH2M PrPs (data not shown). Testing of Hsc70 co-
precipitation with Cy-PrP specific 3F4 antibody revealed a significant Hsc70 signal 
in all analysed samples as well as in the mock and in PM-PrP expressing N2a 
cells (Fig. 25B). However, the amount of co-precipitated Hsc70 was increased by 
about 40 % in the Cy-PrP expressing N2a cells (Fig. 25B, lane 2). Detection of Cy-
PrP and PM-PrP using 3F4 antibody ensured that immunoprecipitation 
experiments worked.  
 
 
Fig. 25 Cy-PrP immunoprecipitation and co-precipitation of Hsc70. Lysates (200 µg) of PonA 
(0.5 µM) induced Cy-PrP-transfected N2a cells were immunoprecipitated with different PrP 
antibodies followed by immunoblot analysis using 3F4 antibody for Cy-PrP and PM-PrP detection 
and additionally anti-Hsc70 in B. (A) Cy-PrP in immunoprecipitates (IP) and supernatants (S) of 
anti-PrP immunoprecipitations using either antibody 6H4 and R340 with dilution 1:500 or SAF32 
with 1:100 dilution. As positive control served 20 µg of pure lysate (L) of transiently Cy-PrP 
expressing N2A cells (B) Immunoblot analysis of Cy-PrP and PM-PrP immunoprecipitations (R340 
anti-PrP) with co-immunoprecipitated Hsc70. Densitometric evaluation of Hsc70 signals from two 
independent experiments are shown as normalised values to mock control (= 1). 
These data suggest that endogenous PrP
C might be a natural substrate for Hsc70 
and additional expression of Cy-PrP increases the amount of co-
immunoprecipitated Hsc70 - a first hint for the regulator function of Hsc70 during 
appearance of cytosolic PrP.  
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4.5 Stable Cy-PrP expressing neuronal cell lines 
4.5.1 Cy-PrP and PM-PrP expressing N2a cells 
The experimental data obtained with transiently Cy-PrP expressing N2a cells 
showed that Cy-PrP is not intrinsically toxic to neuronal cells. However, the 
generation of a stable and constitutive Cy-PrP expressing cell lines failed yet, a 
finding, which was taken as support for the thesis that Cy-PrP mediates 
cytotoxicity (Ma et al. 2002). Since no acute Cy-PrP-mediated cytotoxicity was 
observed in the cellular model in vitro, establishment of stable Cy-PrP expressing 
N2a cell lines could argue against a long term effect on cell survival by Cy-PrP. 
The first attempt to generate stable cellular N2a-clones was done using the 
inducible ecdysone expression system, which was used in transient experiments. 
After transfection or transduction and selection of antibiotic-resistant cellular 
clones, no transactivator VgRXR was expressed on protein level, which hampered 
the expression of Cy-PrP. In the second attempt, the generation of stable clones 
was repeated using the non-inducible CMV-driven Cy-PrP expression plasmid. In 
total, 63 antibiotic-resistant cellular clones were selected and screened by 
immunoblotting using the 3F4 antibody. 43 N2a cell clones positive for Cy-PrP 
expression at different levels were identified (Table 5).  
 
Table 5  Stable Cy-PrP or PM-PrP expressing N2a cell clones 
Transgene  tg-PrP expression level  count of clones 
Cy-PrP +  31 
 ++  7 
 +++  5 
 -  20 
PM-PrP +  6 
 ++  2 
 +++  2 
 -  2 
 
 
 
One representative immunoblot presenting the clones 6, 18 and 25 with highest 
Cy-PrP expressing levels is shown in Fig. 26A. The specific band of around 27 
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kDa for Cy-PrP was detected in all three clones, but not in the parental N2a cells. 
Additional unspecific protein bands were observed at higher molecular weight 
(around 38 kDa) in some of the stable N2a-Cy-PrP cell lines. 
 
 
 
Fig. 26 Stable N2a-Cy-PrP and N2a-PM-PrP cell lines. N2a cells were stably transfected with 
Cy-PrP and PM-PrP followed by puromycin selection. Resistant cell clones were tested on 
transgene PrP expression by immunoblot using 3F4 antibody. Parental N2a cells served as 
negative control. (A) Immunoblot of N2a-Cy-PrP clone 6, 18 and 25. Arrow indicates specific Cy-
PrP band. (B) Immunoblot of N2a-PM-PrP clone 2 and 7.  
In a third step, the control cell lines stably expressing PM-PrP were generated as 
described using CMV-driven PM-PrP construct. Already 10 out of the first 12 
selected antibiotic-resistant clones showed stable expression of PM-PrP (Table 5). 
Immunoblot of the highest PM-PrP expressing N2a clones, 2 and 7, is shown in 
Fig. 26B. The typical three-band pattern of PM-PrP was observed. In contrast, PM-
PrP was not detected in the parental cell line N2a. The efficacy rate to generate 
Cy-PrP and PM-PrP expressing cell lines was 80 % for N2a-PM-PrP cells and 60 
% for N2a-Cy-PrP cells. The successful generation of stable Cy-PrP expressing 
N2a cells might further argue against Cy-PrP-mediated cytotoxicity. 
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4.5.2 Phenotype of N2a-Cy-PrP cell lines 
To test whether Cy-PrP expression might have toxic effects in the stable cell lines, 
several clones were cultivated and examined for their morphology and 
proliferation. Most of the N2a-Cy-PrP clones (> 90 %) showed altered morphology 
in contrast to the parental N2a cells characterised by visual less cytosolic content, 
more ramified and prolonged cell shape and dramatically enhanced cell-cell 
interactions. The latter was already observed in very thin cell culture populations 
and complicated the subcloning procedure (Fig. 27).  
 
 
Fig. 27 Altered morphology of N2a-Cy-PrP cell clones and nuclear chromatin staining. Upper 
lane displays morphology of N2a-Cy-PrP clone 6 and 25 as compared to parental N2a cells. Below 
Hoechst-stained nuclei (blue) of N2a cells and N2a-Cy-PrP cell clones are shown recorded with 
63xPh3 objective of a confocal laser scanning microscope (LSM). Scale bar: 20 µm  
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In contrast, no N2a-PM-PrP clone showed such an altered morphological 
phenotype. N2a-Cy-PrP cell lines did not show reduced proliferation or apoptotic 
morphology such as apoptotic bodies or highly condensed chromatin-structure in 
the nuclei. The latter was examined in Hoechst-stained cells by 
immunofluorescence as shown in Fig. 27. Rather proliferation rate of N2a-Cy-PrP 
cell lines was dramatically accelerated as compared to N2a cells when the 
threshold of critical cell number was exceeded (Fig. 28).  
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Fig. 28  Growth curves and maximal population doubling per day (PD) of stable N2a-Cy and N2a-
PM cell lines and N2a cells. Plot shows cell counts as function of the growing time. Values were 
used for calculation of the maximal PD (right). 
The maximal population doubling rate (PD) of N2a cells and N2a-PM-PrP cell lines 
was around 2.2-2.6 per day (Fig. 28, right). The maximal PD of N2a-Cy25, which 
was the cell clone with the highest Cy-PrP expression, attained 3.7 per day.  
4.5.3 Localisation of Cy-PrP in N2a-Cy-PrP cell lines 
To analyse cellular distribution of Cy-PrP, immunofluorescence experiments were 
performed with different stable N2a-Cy-PrP cell lines. Immunofluorescence 
experiments provided 3F4-specific Cy-PrP staining as red speckles throughout the 
cells as observed in transient transfection experiments and in proximity to plasma 
membrane strongly associated with regions of cell-cell contacts (Fig. 29). To 
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visualise the entire cellular Cy-PrP localisation, projection analyses were 
performed, where all z-layer images were summarised to one image with maximal 
transparency. Partially, the projection image of clone 6 displayed the localisation of 
Cy-PrP in fine foci through the entire cell. In contrast, the highest Cy-PrP 
expressing clone 25 showed a additional strong plasma membrane-like staining. 
 
 
 
Fig. 29  Immunofluorescence of Cy-PrP expression in stable N2a-Cy-PrP cell lines. Cells 
were fixed, permeabilised with Triton-X-100, and stained with mouse anti-PrP antibody 3F4 
antibody followed by Alexa594 (red)-conjugated anti-mouse secondary antibody. Nucleus staining 
was performed with bis-benzimid (Hoechst) solution (blue). Scale bar: 20 µm 
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For the first time, stable N2a-Cy-PrP cell lines were successfully established and 
their characteristics such as accelerated proliferation rate and the lack of apoptotic 
morphology supported the data of viability assays done with transient Cy-PrP 
expressing N2a cells. Therefore, Cy-PrP expression was not toxic per se to 
neuronal N2a cells. Nevertheless, Cy-PrP might affect the cell-cell interactions by 
altered cell adhesion molecule expression.  
4.5.4 Cy-PrP and PM-PrP expressing PrP
0/0 neuronal precursors 
As described above, N2a-Cy-PrP cell lines exhibited an altered morphology 
accompanied by enhanced cell-cell interaction, which might be due to endogenous 
PrP
C/Cy-PrP interaction. To discriminate between Cy-PrP-mediated effects and 
such possibly caused by Cy-PrP/endogenous PrP
C interaction, PrP
0/0 neuronal 
precursor cells were stably transfected with Cy-PrP. So far, one positive Cy-PrP 
expressing cell clone was selected (Fig. 30A), whose morphology was not affected 
by Cy-PrP expression as compared to the control PrP
0/0 neuronal cells. Whether 
PrP
C might have an influence on Cy-PrP function remains to be detailed 
investigated.  
To determine the subcellular localisation of Cy-PrP in these PrP
0/0 neuronal cells, 
immunofluorescence experiments with co-staining of Cy-PrP and EEA1, Hsc70 or 
giantin (Fig. 30B) were performed. Interestingly, Cy-PrP was highly expressed in 
some cells and showed the same staining pattern as in transiently transfected N2a 
cells characterised by nucleus-associated localisation and intense speckles 
throughout the cell (Fig. 30B, 3F4). Furthermore, the immunofluorescence images 
also demonstrated that Cy-PrP co-localises with the endosomal marker EEA1 (Fig. 
30B, upper panel) as well as with Hsc70 (Fig. 30B, middle panel), clearly seen as 
yellow colour in the merged images. As expected, no co-localisation was observed 
of Cy-PrP and giantin (Fig. 30B, lower panel merged image) indicating that Cy-PrP 
is not located in the Golgi apparatus in the PrP
0/0 neuronal precursor cells. 
These data, observed in stable PrP
0/0-Cy-PrP neuronal precursor cells, were in 
accord with the results from transient experiments in N2a cells suggesting that 
Hsc70/Hsp70 might prevent Cy-PrP-mediated cytotoxicity.  
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Fig. 30  Cy-PrP expression in neuronal precursor cells. Stably expressed Cy-PrP in neuronal 
cerebellar precursor PrP
0/0 cells. (A) Immunoblot of Cy-PrP clones Cy7 and Cy4 using 3F4 
antibody. As positive control served transiently transfected N2a cells (lane Cy(N2a)). (B) 
Immunofluorescence analysis of co-stained Cy-PrP (red) with EEA1, Hsc70 or giantin (green). 
Cells were fixed, permeabilised with Triton-X-100, and stained with 3F4 anti-PrP antibody and anti-
EEA1, anti-Hsc70 or anti-giantin antibody followed by Alexa488 (green)-conjugated and Alexa594 
(red)-conjugated secondary antibody. Nucleus staining was performed with bis-benzimid (Hoechst) 
solution (blue) Co-localisation is displayed as yellow colour in the merged images. Scale bar: 20 
µm.  
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5 Discussion 
5.1 Cy-PrP toxicity and proteasome in cell culture 
5.1.1 Cy-PrP is per se not toxic to neuronal cells 
Retro-translocation of proteins from ER to the cytosol is the natural route for 
misfolded and malfunctioning proteins to undergo proteasomal degradation, a 
mechanism also known as ERAD. Recent studies have shown that membrane-
associated PrP and mutant PrP underlie this pathway in neuronal cells (Yedidia et 
al. 2001; Rane et al. 2003; Wang et al. 2005). Ma and colleagues have shown that 
such cytosolic accumulated PrP is toxic to neuronal cells in vitro (2002a) and Cy-
PrP expressed in transgenic mice induces loss of the granular layer of the 
cerebellar neurons in vivo (2002b). However, the postulated cytotoxicity of a 
cytosolic form of PrP is controversial discussed and the mechanisms of 
appearance and action are still not clearly characterised (Fioriti et al., 2005; Heller 
et al., 2003; Rambold et al., 2006; Roucou et. al., 2003; Stewart and Harris, 2003). 
This study investigated the cytotoxic effects of cytosolic PrP in neuronal cells by 
inducible overexpression of a mutant form of PrP (Cy-PrP) lacking the N- and C-
terminal trafficking signals. It was published that this Cy-PrP expression is toxic to 
neuronal N2a cells within 24 h (Ma et al., 2002b; Roucou et al., 2003). To confirm 
this, Cy-PrP was inducible expressed in neuronal N2a cells followed by cell 
viability analyses using the MTT and LDH assay after 24 h and 48 h (Fig. 8). 
Surprisingly, no Cy-PrP-mediated cytotoxicity was measurable. Furthermore, cell 
viability assays performed in 293T cells after 24 h of induced Cy-PrP expression 
(Fig. 10) confirmed the unidentified toxicity in N2a cells. Hence, Cy-PrP was also 
not toxic in non-neuronal cells. It has been shown that Cy-PrP expression in N2a 
cells correlates with increased apoptosis demonstrated by TUNEL assay (Ma et 
al., 2002b) and detection of condensed chromatin with Hoechst 33342 staining 
(Roucou  et al., 2003). Since in this study the TUNEL assay was not clearly 
reproducible, Cy-PrP expressing cells were examined for caspase-3 activity. 
Caspase-3 is the central apoptosis enzyme activated by different apoptosis 
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pathways including ER stress response. Thus, its activity is a reliable marker for 
induced apoptosis in neuronal cells. However, Cy-PrP expression did not induce 
increased caspase-3 activity in N2a cells after 24 h (Fig. 11). It might be possible 
that 24 h Cy-PrP expression was not sufficient to induce apoptosis. But this data 
are contrary to Ma and colleagues who have shown 6 to 14% increase of apoptotic 
N2a cells after 24 h using the same inducible expression system (Ma et al., 
2002b). Others observed only around 25 % Cy-PrP-mediated increased cell death 
24 h post-transfection in N2a cells determined by Hoechst stained condensed 
chromatin in the nuclei (Roucou et al., 2003). However, in this study chromatin-
staining in the nuclei after Cy-PrP expression  showed no increased chromatin 
condensation in N2a cells 24 h post-transfection (Fig. 20, Fig. 22, Fig. 23). One 
might argue that the expression levels of Cy-PrP in several used N2a 
subpopulations were not comparable due to different susceptibility to Cy-PrP-
mediated toxicity. But other neuronal cells were also not susceptible to Cy-PrP-
mediated toxicity (Roucou et al., 2003). Microinjection of Cy-PrP cDNA in human 
neuroblastoma cell lines as well as primary human neurons did not induce cell 
death including 72 h after injection (Roucou et al., 2003). This is further in 
accordance with data obtained for N2a cells overexpressing a mutant PrP, which 
accumulates in the cytosol after proteasome inhibition without showing a cytotoxic 
effect in the MTT viability assay (Fioriti et al., 2005). Furthermore, in this study 
stable Cy-PrP-expressing N2a cell lines were successfully generated, while 
attempts by others failed (Ma et al., 2002b; Roucou et al., 2003). These Cy-PrP 
cell lines with normal or increased proliferation rate and absence of apoptotic 
morphology (Fig. 27-29) are an additional indication that Cy-PrP is not extremely 
toxic. Moreover, neuronal cerebellar precursor cells from Zurich I PrP
0/0 mice were 
used to generate the stable Cy-PrP-expressing cell line Cy4. Even in these cells, 
morphological observations and nuclei visualisation using Hoechst dye were not 
able to detect Cy-PrP-mediated toxicity (Fig. 30). Thus, this study showed several 
lines of evidence that Cy-PrP overexpression is not toxic per se in short-term to 
neuronal cells and the cells might be protected either through recognition and 
degradation of Cy-PrP or binding of Cy-PrP to protective proteins.  
Considering that neurodegeneration often appears with aging including inherited 
prion diseases and displays a long-term process, analysis of Cy-PrP involved in 
this process by transient transfection experiments may not be suitable. The 
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generated stably expressing Cy-PrP cell lines are an ideal starting point to 
investigate whether long-term Cy-PrP expression is detrimental to the cells by, for 
instance, analysis of Cy-PrP expression levels, Cy-PrP aggregation, and effects 
on cell growth and cell viability.  
5.1.2 Stability and proteolysis of Cy-PrP 
In most prion diseases, it has been shown that neuropathology is accompanied 
with widespread deposits of amyloid aggregates containing the structural 
converted PrP
Sc (Collinge, 2001; Hope, 2000; Jackson and Clarke, 2000). Since 
then, the ability of derivatives of PrP
C, such as PrP
Sc, to form aggregates has been 
often used as parameter for neuronal toxicity. A characteristic of these detergent 
insoluble aggregates is their resistance to proteinase K digestion (Bolton et al., 
1982, McKinley et al., 1983). However, no proteinase K resistant Cy-PrP was 
found after 16 h PonA induction in the used cellular model (Fig. 12). A second 
indicator for PrP
Sc-like aggregation is the increased stability and prolonged half life 
as compared to PrP
C (Borchelt et al., 1990). However, it was demonstrated that 
overexpressed Cy-PrP is degraded like a short living protein similar to PrP
C 
(Borchelt et al., 1990). The proteolysis rate of Cy-PrP with the half life around 7.5 h 
was comparable to that of overexpressed full length PrP (PM-PrP) (Fig. 13). These 
findings support the lack of intrinsic Cy-PrP toxicity to N2a cells due to missing 
increased proteolysis and stabilisation as aggregates. Similar observations were 
obtained from experiments done with recombinant mPrP(23-231) (Hornemann et 
al., 1997). Recombinant mPrP(23-231) is soluble, sensitive towards proteolytical 
digestion and does not aggregate irreversible in aqueous solution in vitro. 
However, Wang and colleagues failed to precipitate Cy-PrP using the 3F4 
antibody, which was also found in this study (see 4.4.3), and assumed that Cy-PrP 
is aggregated due to the removal of such aggregates during the pre-clear 
centrifugation step within the procedure of immunoprecipitation (Wang et al., 
2005). In contrast, the precipitation of Cy-PrP worked well using antibodies 
recognising epitopes up- and down-stream of the 3F4-epitope (Fig. 25). This result 
does not further support this postulated aggregation theory. However, the 3F4-
epitope might cover a binding site with higher affinity to other proteins such as 
already postulated for PrP
Sc (Brown, 2000; Norstrom and Mastrianni, 2005; Satoh 
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et al., 2005; Zanata et al., 2002) and might explain the failed precipitation using 
the 3F4 antibody. Finally, Cy-PrP aggregates might exist and their formation 
depends on the cytosolic concentration, the intracellular localisation, and the 
kinetics between synthesis and degradation of Cy-PrP as well as the interaction 
with other cellular proteins. 
In different neurodegenerative diseases and during aging proteasome activity is 
reduced, which causes accumulation of misfolded and malfunctioning proteins 
(Grune et al., 2005; Keller et al., 2000; Keller et al., 2005; Korolainen et al., 2002). 
Accumulation of misfolded proteins is suggested to be the common pathogenic 
mechanism in some neurodegenerative disorders including prion disease. Thus, 
the Cy-PrP proteolysis was further detailed analysed for the responsible protease 
with the proteasomal system as primary target for investigations. Indeed, Cy-PrP 
proteolysis after proteasome inhibition was dramatically decelerated indicated by 
prolonged half life of around 12 h (Fig. 14), which is comparable with that of PrP
Sc 
(half life 15 h). Additionally, strong Cy-PrP accumulation was observed after 
proteasome inhibition (Fig. 16). Both results indicate that Cy-PrP is recognised 
and degraded by the proteasome. Strikingly, no influence on cell viability was 
detected during inhibition of proteasomal activity (Fig. 18). The Cy-PrP expression 
neither increased the proteasome activity nor altered the entire proteasome level 
in N2a cells (Fig. 17). The presented data together with the PK-digestion 
experiment do not confirm previous suggestions, that cytosolic accumulated PrP 
will aggregate, and aggregated PrP molecules are resistant to further degradation 
and might trigger cytotoxicity (Ma et al., 1999; Ma et al., 2002a). However, long-
term Cy-PrP expression might cause Cy-PrP aggregation by a yet unknown 
mechanism. In further studies using the generated N2a-Cy-PrP cells, Cy-PrP 
aggregation might be detectable through higher molecular weight of Cy-PrP 
signals with increasing number of cell passages. Moreover, the fibrilar character of 
Cy-PrP aggregates could be analysed via the specific amyloid fibril staining with 
Thioflavin S or (trans, trans)-1-bromo-2.5-bis-(3-hydroxycarbonyl-4-hydroxy) 
styrylbenzene (BSB) in a time-dependent manner (Ando et al., 2003; Hoefert et 
al., 2004; Konarkowska et al., 2006; Santa-Maria et al., 2006).  
Finally, it has to be mentioned that continuous Cy-PrP expression appears to 
increase the ATP-dependent proteasome activity in the N2a-Cy-PrP cell lines 6 
and 25 (data not shown) as compared to parental N2a cells. This changed 
72 Discussion 
proteolytical activity could signalise a continuous stress situation, which has only 
consequences during prolonged cultivation.    
5.1.3 Retro-translocated Cy-PrP 
PrP accumulation in the cytosol has been shown clearly, however the nature of 
such cytosolic PrP is controversially discussed. Different studies using stable cells 
expressing wt-PrP or mutant PrP demonstrate accumulation of a non-glycosylated, 
N-terminal signal peptide-bearing form of PrP (NSP-PrP) in the cytosol during 
proteasome inhibition (Drisaldi et al., 2003; Fioriti et al., 2005). This small fraction 
of NSP-PrP appears not to be translocated into the ER. The authors claimed that 
PrP is not subjected to ERAD and the natural occurrence of Cy-PrP is therefore 
unlikely. In fact, they discussed that observed cytosolic NSP-PrP is a result of 
elevated transgenic PrP expression due to proteasome inhibitor-mediated 
increased CMV-promotor activity followed by overloaded ER translocation. In 
contrast, detailed analysis of endogenous wt-PrP in several cell lines and primary 
neurons revealed that a portion of PrP is retro-translocated to the cytosol for 
degradation by the proteasome (Wang et al., 2005). Consistent with these data, 
the accumulation of a non-glycosylated PM-PrP isoform was found during 
proteasome inhibition in PM-PrP overexpressing N2a cells (Fig. 15), although PM-
PrP expression was already stopped. The occurrence of this form of PrP cannot 
be the result of increased PM-PrP synthesis by epoxomicin-mediated elevated 
CMV-promoter activity. The molecular weight of this form of non-glycosylated PrP 
was slightly higher as compared to overexpressed transgenic Cy-PrP (e.g. Fig. 
7Fig. 9Fig. 19). The NSP contains 23 aa, which would result in an additional 
molecular weight of approximately 2.5 kDa. This supports the theory of retro-
translocated PrP carrying the NSP, which becomes visible. To confirm this, PM-
PrP expressing N2a cells have to be analysed by immunoblotting using a specific 
anti-NSP antibody (Stewart and Harris, 2003). On the other hand, PM-PrP like 
PrP
C undergoes a variety of proteolytic processing events and another proteolytic 
form of PM-PrP might be detected, which is not related to retro-translocation into 
the cytosol. For instance, PrP
C can be cleaved at aa 110 and 111 by ADAM family 
proteases such as ADAM 10 and ADAM 17 to produce a 17-kDa C-terminal 
fragment C1 (Jimenez-Huete et al., 1998; Pan et al., 1992; Shyng et al., 1993). 
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PrP
C can also be cleaved by ROS within or adjacent to the octarepeats to 
generate a 21-kDa C-terminal fragment C2 (Jimenez-Huete et al., 1998; Pan et al., 
1992; Taraboulos et al., 1992). However, both proteolytical cleavage products of 
PM-PrP would provide lower molecular weight signals as compared to transgenic 
Cy-PrP of around 27 kDa. Thus, the appearance of NSP-PrP derived from PM-PrP 
becomes more evident.  
In addition, if PrP is mainly post-translational imported into ER, the putative 
transmembrane domain of PrP will induce misfolding in the cytosol interfering the 
import into the ER (Heller et al., 2003). Such non-glycosylated and misfolded NSP-
PrP associates with the ER membranes and decreases cell viability (Heller et al., 
2003). In contrast, Heller et al. showed that expressed Cy-PrP also adopts a 
misfolded conformation; however, this has no adverse effect on cell growth. In this 
study, accumulated non-glycosylated PM-PrP (Fig. 15) was not significant toxic 
after 24 h PM-PrP expression in presence of proteasome inhibition in N2a cells 
(Fig. 18). Continuous PM-PrP overexpression might cause saturation of ER-
translocation and could result in the accumulation of NSP-PrP and cell death, 
which needs further investigation. On the other hand, retro-translocation of 
misfolded or malfunctioned proteins involves Ca-dependent ER chaperones like 
Bip and calnexin. By this way a continuous traffic jam of misfolded or 
malfunctioned PrPs in the ER might cause alterations in the Ca-homeostasis 
(Bushmarina et al., 2006; Verkhratsky, 2002; Zhang and Kaufman, 2006) followed 
by ER-stress response and apoptosis (Ferreiro et al. 2006; Hetz et al., 2003; 
Kristensson et al., 1993; Sandberg et al., 2004; Wong et al., 1996; Yadavalli et al. 
2004).   
Taken together the presented data support that cytosolic PrP is a result of ER 
retro-translocation, but cytotoxicity might be triggered by not retro-translocated 
NSP-PrP generated by impaired ER import during or after translation. These 
findings further let conclude that high levels of Cy-PrP escaped from proteolysis 
and an impaired proteasome system are not sufficient to induce Cy-PrP-mediated 
neuronal cell death. Furthermore, cell type and cell line, respectively, might 
determine the tolerance against the Cy-PrP and NSP-PrP in the in vitro 
experiments.  
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5.1.4 Cy-PrP/membrane interaction as toxic event 
One recent publication showed that Cy-PrP-mediated cytotoxicity is due to 
association of Cy-PrP with membranes (Wang et al., 2006), since Cy-PrP 
expressed in N2a cells migrates with endogenous PrP and calnexin in the 
membrane fraction of sucrose gradients. Previous studies indicated that PrP 
interacts with lipids (Baron and Caughey, 2003; Kazlauskaite et al., 2003; Morillas 
et al., 1999; Sanghera and Pinheiro, 2002) and that recombinant PrP can bind and 
disrupt liposomes composed of negatively charged phospholipids (Kazlauskaite et 
al., 2003). One might speculate that Cy-PrP disrupts the phospholipid bilayer via 
interaction with the hydrophobic core of membranes, causing increasing calcium 
concentration and increasing levels of calcium-responsive phospholipase (cPLA2), 
as observed in degenerating cerebellum of transgenic mice expressing Cy-PrP 
(Wang et al. 2006). However in this study Cy-PrP was mainly separated with the 
soluble cytosolic fraction (Fig. 19). Only a small part of Cy-PrP was associated 
with the plasma membrane/ER membrane fraction as observed for the full length 
PM-PrP and no Cy-PrP-mediated toxicity was found (Fig. 8, Fig. 10 and Fig. 11). 
Thus, the postulated mechanism of the Cy-PrP-mediated impairment of calcium 
homeostasis via membrane disruption and cPLA2 activation as toxic signal 
cascade is inconsistent with these data. Furthermore, neurons in the forebrain 
tolerate higher amounts of Cy-PrP and do not show neuronal death in vivo (Wang 
et al. 2006). It is rather likely that Cy-PrP degradation (see 4.3.1) and interaction 
with protective cytosolic proteins prevents neuronal N2a cells from this 
mechanism.  
5.2 Cy-PrP localisation in early endosomal vesicles 
This study showed cytosolic localisation of Cy-PrP by immunoblot analyses of 
cytosolic and membrane fractions (Fig. 19). Immunofluorescence microscopy 
revealed a strong co-localisation of Cy-PrP with EEA1, a marker for early 
endosomes (Lawe et al., 2000; Mu et al., 1995, Wilson et al., 2000)(Fig. 22). Early 
endosomes are low density vesicles more present in the cytosol than in the high 
density membrane fractions (Bergeron et al., 1986; Kjeken et al., 1995; Shah et 
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al., 2006). EEA1 is a hydrophilic peripheral membrane protein partitioning in the 
aqueous phase after triton-detergent solubilisation as used here (Mu et al., 1995). 
Thus, both data were convergent to exclude that Cy-PrP is mainly plasma 
membrane-located. It was rather that high amount of Cy-PrP localised intracellular 
in EEA1-positive endosomal vesicles in transient Cy-PrP expressing N2a cells 
(Fig. 22). Further experiments to separate early and late endosomes as well as 
lysosomes using OptiPrep iodixanol density gradient (Axis Shield) would support 
the observed data. Lysosomal markers like “lysotracker green” and LAMP1 have 
been failed in immunofluorescence experiments (data not shown) and analyses 
using NH4Cl, as inhibitor of lysosomal proteases provided no hint for lysosomal 
degradation of Cy-PrP (data not shown).  
Firstly, EEA1 functions as tethering/docking molecule that provides directionality to 
the vesicular transport from the plasma membrane to the early endosomes 
(Rubino et al., 2000; Wilson et al., 2000). EEA1 is exclusively localised to early 
endosomes and not present in clathrin-coated vesicles (CCV) (Rubino et al., 2000; 
Wilson et al., 2000). These data let conclude that co-localisation of Cy-PrP with 
EEA1 represents a Cy-PrP transport to the early endosomal compartment. This 
process might be triggered by the N-terminal domain of Cy-PrP, containing the 
basic motive NH2-KKRPK, which is also sufficient for direct internalisation of PrP
C 
(Sunyach et al., 2003; Taylor et al., 2005). This can be tested using a truncated 
Cy-PrP (aa27-231) or via alanine-scanning mutagenesis. 
Secondly, other authors postulated a direct interaction of Cy-PrP with the plasma 
membrane, which could trigger EEA1-mediated docking at this locations followed 
by uptake of Cy-PrP into early endosomes to prevent disruption of cell membrane 
associated cell signalling or transport function. These vesicular inclusions could 
reduce levels of diffuse Cy-PrP in the cytosol and the risk of neuronal death as 
observed for huntingtin in primary neurons (Arrasate et al., 2004). EEA1 uptake 
within the endosomal membrane and its function are dependent on PI(3)P, Rab5-
GTP and calmodulin binding (Lawe et al., 2000; Lawe et al., 2003; Rubino et al., 
2000; Simonsen et al., 1998). Reduction of EEA1 or Rab5-GTP through RNA 
interference as well the inhibition of calmodulin binding by the specific inhibitor 
W7, which showed already re-localisation of EEA1 to the cytosol (Lawe et al., 
2003), might increase Cy-PrP-mediated cytotoxicity in N2a or other cellular 
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models. This would demonstrate both, Cy-PrP is toxic to cells and the endosomal 
compartment plays a pivotal protective function. 
Thirdly, internalisation of mature PrP
C is mediated by clathrin coated pits into 
recycling endsomes from which it is rapidly retrieved to the cell membrane (Shyng 
et al., 1994; Sunyach et al., 2003; Taylor et al., 2005). During this process PrP
C 
passes Rab5-containing early endosomes (Magalhaes et al., 2002; Sunyach et al., 
2003). Cy-PrP located in early endosomes could interact with mature PrP
C. If Cy-
PrP has conformational similarities to PrP
Sc as postulated by Ma and colleagues 
(Ma et al., 1999; Ma et al., 2002a) and the known fact that early endosomes are 
identified as potential sites for the generation of PrP
Sc by PrP
Sc/PrP
C interaction 
(Biswas et al., 2006; Brown, 2000; Feughelman and Willis, 2002; Norstrom et al., 
2005; Warwicker, 2000), it might be possible that Cy-PrP mediates conversion of 
PrP
C to a PrP
Sc-like isoform and contributes to neuronal death in a time dependent 
manner. In fact, this study demonstrated that Cy-PrP is not PK-resistant and forms 
no proteolysis-resistant aggregates like PrP
Sc, since Cy-PrP was completely 
degraded by the proteasome. 
Fourthly, Cy-PrP could interact with PrP
C in a toxic manner by inhibition of the 
signalling function of PrP
C in vivo, e.g. within the Fyn-kinase pathway, on neuronal 
differentiation and survival (Chen et al., 2003; Kanaani et al., 2005; Santuccione et 
al., 2005; Steele et al., 2006) as well as during neuronal activation via synaptic 
vesicles. Furthermore, interaction of Cy-PrP with other membrane associated 
proteins than PrP
C might be also a toxic event in vivo, especially when it occurs 
closely to synaptic membranes (Wang et al., 2006). In support to this hypothesis, 
Cy-PrP was observed in close proximity to the plasma membrane, mainly in 
regions of cell-cell contacts, in the highest stable Cy-PrP expressing N2a cell line 
(Cy25)(Fig. 29, middle panel). Cy-PrP-mediated effects on neuronal cell-cell 
communication, synaptic neurotransmitter release and neuronal differentiation 
could be examined using primary neurons followed by in vivo studies with mice 
expressing Cy-PrP in neuronal subtypes. However, toxic accumulation of Cy-
PrP/PrP
C complexes might be rather a long-term effect. It has to be therefore 
analysed, whether continuous Cy-PrP expression has an effect on the PrP
C level 
on the plasma membrane or endosomal aggregation as well as on the Fyn kinase 
signalling. Thus, further investigations using the generated stable N2a-Cy-PrP cell 
lines would be helpful to answer these questions. 
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5.3 Hsc70/Hsp70 - prevention against Cy-PrP toxicity 
The lack of Cy-PrP cytotoxicity in the used N2a cell model could also been due to 
the existence of a secondary defence system against the toxic accumulation of 
Cy-PrP in neuronal cells. The major difference between the normal and disease-
associated isoforms of PrP is a conformational change, leading to the hypothesis 
that chaperones may be involved in the folding of PrP and hence in the 
progression of the disease (Kenward et al., 1996; Telling et al., 1995). Hsp70 
family appears to play a particular role in prion disease, since it has been shown 
that Hsp70 co-localises with ubiquitin-protein conjugates in vesicle structures of 
the endosome/lysosome system of scrapie-infected mouse brain (Arnold et al., 
1995; Laszlo et al., 1992). Regarding cytosolic PrP, ER retro-translocated PrP co-
localises with Hsc70 in aggresomes after proteasome inhibition (Ma et al., 2001). 
In this study Cy-PrP co-localisation with Hsc70 in EEA1-positive vesicle structures 
was observed at higher expression levels.  The expression level of Hsc70 was not 
affected by Cy-PrP expression in N2a cells (Fig. 24). However, Cy-PrP seems to 
have a redistributing effect on Hsc70 (Fig. 23), since in mock and PM-PrP-
expressing N2a cells Hsc70 staining was diffuse and showed homogenous cellular 
Hsc70 distribution, which was lost in favour of Hsc70 focal aggregation in Cy-PrP-
expressing N2a cells. This is consistent with data obtained with the inducible 
Hsc70-counterpart Hsp70 and the co-chaperone Hsp40, which co-localise after 
proteasome inhibition with cytosolic PrP in immunofluorescence experiments and 
sucrose gradient fractions (Rambold et al., 2006). Moreover, Cy-PrP co-
immunoprecipitates with Hsp70 indicating that the cytosolic chaperone Hsp70 
interacts with Cy-PrP. It has been shown that in vitro Hsp70 and Hsc70 interact 
with lipids and promote the liposome aggregation in a time and protein 
concentration dependent manner (Arispe et al., 2002; Ma et al., 2001). 
Furthermore, accumulated inducible Hsp72 protects Purkinje cells against cell 
death in Creutzfeldt-Jacob disease (CJD) (Kovacs et al., 2001) and Hsp70/Hsc70 
reduces huntingtin toxicity and aggregation in neurons (Novoselova et al., 2005; 
Warrick et al., 1999). In SH-SY5Y human neuroblastoma cells, Hsc70 and Hsp40 
overexpression prevents cytosolic PrP-induced apoptosis (Rambold et al., 2006). 
The cytoprotective activity of Hsp70/Hsc70 is thought to be related to its 
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chaperone activity (Nollen et al., 2002). Taken together, these data support the 
findings in this study indicating that Cy-PrP cytotoxicity in neuronal cells could be 
prevented by the protective function of high levels of Hsc70. What might be the 
molecular mechanism of Hsc70/Cy-PrP interaction (Fig. 31)? 
Cy-PrP produced by retro-translocation (Jin et al., 2000; Ma et al., 2001; Roucou 
et al., 2003; Wang et al., 2005; Zanusso et al., 1999) or impaired import into the 
ER (Heller et al., 2003; Rane et al., 2004) is degraded by the proteasome (Fig. 
14). Thereby, hydrophobic residues of translated Cy-PrP are recognised by 
Hsc70, which promotes the folding process through cycles of substrate binding 
and release regulated by their ATP activity (Hartl and Hayer-Hartl, 2002; Rudiger 
et al., 1997). Function of such Hsc70/Cy-PrP complexes is dependent on co-
chaperone binding (Hohfeld et al., 1995; Hohfeld and Jentsch, 1997; Minami et al., 
1996). ER-associated degradation (ERAD) of Cy-PrP by the proteasome might be 
mediated by binding of co-chaperone BAG-1 to the Hsc70/Cy-PrP complex. BAG-
1 binds the proteasome and interacts with the ubiquitin-ligase CHIP followed by 
Cy-PrP release from Hsc70, Cy-PrP ubiquitination and proteasomal degradation 
(Alberti et al., 2002; Luders et al., 2000). It has to be mentioned that the cellular 
level of BAG-1 is approximately 1 % of Hsp70 (Nollen et al., 2000; Nollen et al., 
2002; Takayama et al., 1997) indicating that BAG-1 can bind only a fraction of 
Hsp/Hsc70 molecules. Otherwise, when Cy-PrP formation overcomes its 
proteolytical removal, excess Cy-PrP molecules interact with Hsc70, whose 
chaperone activity controls Cy-PrP folding in order to prevent cytotoxic 
aggregation. Although Hsc70 co-immunoprecipitation with PrP was increased in 
the Cy-PrP expressing cells, the binding of Cy-PrP by Hsc70 was not clearly 
demonstrated in this study. Therefore, in vitro binding assays such as 
plasmonresonance spectroscopy with purified Cy-PrP and Hsc70 could provide 
information about Cy-PrP/Hsc70 interaction. Furthermore, usage of distinct PrP 
peptides, e.g. PrP106-126, or truncated PrP isoforms could help to identify the Cy-
PrP/Hsc70 binding site in PrP.  
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Fig. 31 Model of Cy-PrP metabolism – cytotoxicity versus prevention by Hsc70. ER imported 
nascent PrP binds luminal chaperone Bip; transport to Golgi compartment following correct 
chaperone-mediated folding (e.g. calnexin); misfolded or incorrect modified (N-glycosylation) PrP is 
retro-translocated via sec61 to the cytosol, named Cy-PrP. Cy-PrP can be toxic by (Wang et al. 
2006) disruption of the intracellular membranes and the plasma membrane or by endosomal 
interaction with clathrin-endocytosed PrP
C in fused clathrin coated vesicles (CCV) and early 
endosomes, also mediated by Hsc70 (clathrin uncoating). The latter likely might be an in vivo effect 
resulting in an impaired synaptic vesicle recycling or neurotransmitter release or PrP
C signalling. 
Thereby, direct Cy-PrP traffic to CCVs/early endosomes might be triggered its N-terminal basic 
tetra peptide KKRP. However, Hsc70 also appears to have protective potential against Cy-PrP 
induced toxicity, maybe dependent on the Hsc70 level and the energy stage (ATP). Theoretically, 
Cy-PrP could bind Hsc70 via its hydrophobic core (aa) followed by BAG1- and CHIP-mediated 
proteasomal degradation. Excess Cy-PrP remains bound to Hsc70 to avoid uncontrolled 
aggregation, and it is translocated to early endosomes to remove Cy-PrP from the cytosol. Later 
on, Hsc70-mediated re-traffic of Cy-PrP to the cytosol is assumed for further proteasomal 
degradation. Therefore, the steady state level of Cy-PrP and chaperones, particularly Hsc70, as 
well as the availability of ATP and synaptic activity determine Cy-PrP-mediated cytotoxicity in vivo.     
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To remove the potential toxic Cy-PrP from cytosol, Hsc70 might mediate Cy-PrP 
translocation across intracellular membranes into endosomal vesicles 
(Agarraberes et al., 2001; Arispe et al., 2002; Cuervo et al., 1997; Terlecky et al., 
1992) explaining the observed co-localisation of Cy-PrP and the endosomal 
marker EEA1 (Fig. 22 and 30). It is known that cytosolic proteins are internalised 
and degraded in lysosomes in a Hsc73-mediated fashion (Chiang et al., 1989; 
Terlecky et al., 1992) However, further Cy-PrP degradation by lysosomes after 
delivery to the endosome/lysosome system by Hsc70-mediated transport is not 
assumed (see 5.2, first section). 
Nevertheless, in vivo Cy-PrP expression level varies in different brain regions and 
is extremely toxic to granular cerebellar neurons in transgenic mice (Ma et al., 
2002b; Wang et al., 2006). Such observed neuronal cell type-dependent 
cytotoxicity might be due to differences in the synaptic excitation or anti-stress 
systems, as chaperone response as well as ubiquitin-proteasome system. Indeed, 
the basal expression level of Hsc70 and the stress induced expression of Hsp70 
vary in several neuronal cell types (Belay et al., 2006; Foster et al., 1995; Guzhova 
et al., 2001; Manzerra et al., 1996; Tanaka et al., 2002; Voisin et al., 1996). 
Neuronal cell types that exhibit high levels of Hsc70, such as specific hippocampal 
neurons and cerebellar Purkinje cells, are not triggered to undergo stress-induced 
cell death as compared to other neuronal populations such as granular cerebellar 
neurons lacking Hsc70 (Belay et al., 2006; Tanaka et al., 2002). Furthermore, high 
level of constitutively expressed Hsc70 appears to have a damping effect on 
stress-induced Hsp70 expression (Foster et al., 1995; Manzerra et al., 1996). 
Moreover, a 10-fold reduction in Hsp70 basal expression was observed upon 
differentiation in neuroblastoma cells (Guzhova et al., 2001). Thus, the 
differentiation state and pool of chaperones expressed in different neuronal cell 
types may contribute to Cy-PrP mediated cytotoxicity in vivo. All these findings 
support our data obtained in the N2a neuroblastoma cell model and demonstrate 
that distinct chaperone expression is connected to neuroprotection. Concerning 
Cy-PrP-mediated cytotoxicity and the postulated hypothesis of Cy-PrP triggered 
membrane disruption (Wang et al., 2006), a participation of Hsp70/Hsc70 has to 
be considered, since these chaperones are present in lipid raft in cells of forebrain 
and cerebellum (Chen et al., 2005). Interestingly, in CJD patients it has been 
shown that neuropathological changes are mainly restricted to cell populations or 
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brain regions in which Hsp70/Hsc70 was expressed at lower levels. Indeed, 
apoptosis induction was higher in the Hsp70-negative granular cell layer as 
compared to Purkinje cells, which express high Hsp70 levels. Moreover, brain 
regions showing severe spongiform changes and gliosis exhibit fewer Hsp70-
immunoreactive neurons (Kovacs et al., 2001).  
In addition, it should be investigated whether neuronal differentiation has an 
influence on the Hsc70/Hsp70 pool and can reveal Cy-PrP-mediated toxicity in 
stable N2a-Cy-PrP cell lines and PrP
0/0-Cy4. In order to prove the hypothesis that 
Hsc70 prevents Cy-PrP-mediated toxicity in N2a-Cy-PrP cells, siRNA approaches 
could be performed to knock down Hsc70 expression followed by viability and 
apoptosis assays in these cells.  
5.4 Cy-PrP and N2a cell morphology  
During the generation of stable Cy-PrP expressing N2a cells most of the selected 
cell clones exhibited a new morphology characterised by visual less cytosolic 
content, more ramified and prolonged cell shape and dramatically enhanced cell-
cell interactions (Fig. 29). Surprisingly, this phenotype was not found in any of the 
N2a-PM-PrP cell lines. These observations might indicate a Cy-PrP-mediated 
alteration of cell adhesion. To ensure that this phenomenon is due to the 
expression of Cy-PrP, the protein could be knocked down by a siRNA approach to 
return the morphology to the parental cells. This would be a novel unpublished Cy-
PrP-mediated effect in neuronal cells. Nevertheless, analyses of several adhesion 
molecules such as E/N-cadherine, p120, α- and β-catenin or NCAM as well as 
members of signalling cascades like Akt1/2 and SRC phosphorylation would be 
suggestive to examine, how Cy-PrP might influence this complex cell adhesion 
system. Interestingly, the selected Cy4 clone derived from PrP
0/0 cells showed no 
altered phenotype as compared to the parental cells. Hence, N2a-Cy-PrP 
phenotype might be a result of Cy-PrP and endogenous PrP
C interaction, e.g. in 
the endosomal compartment (see 2.2.2 and 5.2). Therefore, generated N2a-Cy-
PrP cell lines are potent cellular models to analyse Cy-PrP effects on cell adhesion 
in presence of endogenous level of PrP
C.  
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5.5 Putative consequences for Cy-PrP expression in vivo 
Co-localisation of Cy-PrP with EEA1 (Fig. 22Fig. 30) and Hsc70 (Fig. 22Fig. 23Fig. 
30) arise the question of its consequences for the neuronal interaction in vivo. It is 
known that early endosomes and Hsc70 are important for the synaptic function 
and the recycling of synaptic vesicles as well as different neurotransmitter 
receptors (Bronk et al., 2001; Buchner and Gundersen, 1997; Holroyd et al., 1999; 
Selak et al., 2004; Selak and Fritzler, 2004; Shimizu et al., 2003; Stahl et al., 1999; 
Tobaben  et al., 2001; Washbourne et al., 2004; Zinsmaier and Bronk, 2001). 
Hence, the speculated Hsc70-mediated transport of Cy-PrP to early endosomes 
within synaptic areas might influence the normal synaptic vesicles maturation and 
the neurotransmitter release. Such Cy-PrP induced synapsis dysfunction in vivo 
could explain the contradicting results concerning the Cy-PrP toxicity observed in 
different cell models in vitro. Furthermore, PrP
C plays a role in the fine-tuning of 
synaptic activity and plasticity examined in PrP knock out mice (see also 2.2.3). 
These results are supported by the fact that recombinant PrP induces rapid 
polarisation and development of synapses in embryonic rat hippocampal neurons 
(Kanaani et al., 2005). Assumed Cy-PrP/PrP
C interactions in the endosomes might 
result in similar neuropathological effects as detected in prion-diseased brains, 
maybe due to loss of normal PrP
C function. In the cerebellum of CJD patients PrP 
deposits accumulated in the synapses correlating with abnormal synaptic protein 
expression (Ferrer, 2002). Scrapie-infected mice showed also synapses loss 
associated with abnormal PrP precedes (Jeffrey et al., 2000), intrinsic dysfunction 
of cortical and hippocampal neurons (Jefferys et al., 1994) and altered properties 
of the membrane and synapses (Johnston et al., 1997). Moreover, it has been 
speculated that PrP
C may be a constituent of the synaptic vesicle membrane 
(Fournier  et al., 1995) and affects the neurotransmitter release via synaptic 
vesicles as shown for acetylcholine in neuromuscular junction (Re et al., 2006). 
Thus, Cy-PrP localisation in endosomes followed by its presence in synaptic 
vesicles could have disastrous consequences for the neuron-neuron signalling and 
synaptic plasticity in the brain, when Cy-PrP impairs the PrP
C and Hsc70 function 
during synaptic vesicle maturation, release and their recycling process. 
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aa     amino acid 
A   adenosine 
AMC   7-amino-4-methylcoumarin 
Asn     asparagines 
ATP   adenosine  tri-phosphate 
BCA   bicinchoninic  acid 
BFGF   basic fibroblast growth factor 
bp     base pair 
BSA    bovine serum albumin 
BSB   [(trans,trans),-1-bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy) 
styrylbenzene 
BSE     bovine spongiforme encephalopathy 
CJD     Creutzfeldt-Jakob disease 
CMV   cytomegalovirus 
cPLA2   calcium-dependent cytosolic phospholipase A2  
Cy-PrP  prion protein containing amino acids23-231 
d     days 
DMEM  “Dulbecco´s modified Eagle´s medium” 
DMSO dimethyl  sulfoxide 
DNA     deoxyribonucleic acid 
DTT   dithiothreitol 
EDTA   ethylene diamine tetra-acetate 
EEA1   early endosomal antigen 1 
EndoH Endoglycosidase  H 
Epoxo   epoxomicin 
ER   endoplasmatic  reticulum 
ERAD   endoplasmatic reticulum associated degradation 
FACS   flow cytometry 
FFI    fatal familial insomnia 
Fig   Figure 
FITC     fluorescence isothiocyanate 
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GFP    green fluorescence protein 
GSS   Gerstmann-Sträussler-Scheinker  disease 
GPI     glycosylphosphatidylinositol 
h     hours 
Hsp    heat shock protein 
Hsc    cognate form of heat shock protein 
Ig     immunoglobulin 
IB   immunoblotting 
IP   immunoprecipitation 
IF   immunofluorescence 
kb   kilobasepairs 
kDa   kilodalton 
l   litre 
LDH     lactate dehydrogenase 
LB   Luria  Bertani 
µg     microgram 
MH2M   chimeric  mouse-hamster-mouse prion protein 
min     minutes 
ml     millilitre 
MTT   3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
N2a     murine neuroblastoma cell line 
NSP     N-terminal signal peptide 
NTPs   nucleoside triphosphates 
OD   optical  density 
PBS    phosphate buffered saline 
PCR    polymerase chain reaction 
PDI    protein disulfide isomerase 
PEI   Paul-Ehrlich-Institut   
PFA   paraformaldehyde 
PK     proteinase K 
PM-PrP  plasma membrane located full length prion protein 
PMSF   phenylmethylsulfonylfluoride 
Prnp    mouse prion protein gene 
PrP
C     cellular prion protein 
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PrP
0/0   PrP
C knock out (Zurich I) cerebellar neuronal precursor cell line 
PrP
Sc    pathogenic isoform of the prion protein 
R340    polyclonal anti-PrP antibody 
RPE   R-phycoerythrin   
RT   room  temperature 
SAF32  anti-PrP antibody binding the N-terminal region 
SDS     sodium dodecyl sulfate 
SDS-PAGE  sodium dodecyl sulfate polyacrylamid gel electrophoresis 
sec     seconds 
6H4    anti-PrP antibody binding epitope aa144-152 
Tab   table 
TAE   Tris-acetate-EDTA 
TD   annealing  temperature 
Tris   Tris-(hydroxymethyl)-aminomethane 
TSE     transmissible spongiform encephalopathies 
TUNEL  terminal-dUTP nick end labelling 
wt     wild-type 
3F4   PrP-specific  monoclonal  antibody binding epitope aa109-112 
293T    human embryonal kidney cell line expressing the large T antigen 
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